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ABSTRACT
STUDIES OF THE EFFECTS OF PANCREATIC BETA CELL ANTIOXIDANT TRANSGENES
ON EXPERIMENTAL MODELS OF DIABETES

Hainan Chen
August 21, 2003

Pancreatic beta cells are extremely vulnerable to the destruction of Reactive Oxygen Species
(ROS). In both type 1 and type 2 diabetes ROS are involved in the loss of p-cells. We hypothesized that
the deficiency in ROS detoxifying system of p-cells resulted in p-cell vulnerability and enhanced ROS
protection would protect from diabetes. To test this hypothesis, transgenic mice with overexpression of pcell antioxidant protein metallothionein (MT), manganese superoxide dismutase (MnSOD) and catalase
were produced on an FVB background. Initial studies demonstrated that these trans genes did not affect pcell normal function and morphology. But those transgenes significantly protected pancreatic islets or mice
from ROS induced p-cell damage and diabetes. The transgenic islet cells had high efficacy in scavenging
most forms of ROS, and generally survived and functioned better than control cells when exposed to
various ROS insults. The transgenic mice were highly resistant to STZ induced diabetes.

However, inconsistent with studies on insulin secreting tumor cell lines in which antioxidants
were shown to be protective, all these antioxidant trans genes failed to prevent cytokine toxicities in the
cultured islets. We employed a speed congenic strategy to produce two lines of congenic NOD mice
containing p-cell specific expression of MT and catalase. NOD mice spontaneously develop type 1
diabetes, and cyclophosphamide (CYP) injection accelerates NOD diabetes onset. But very unexpectedly,
either trans gene MT or catalase dramatically hastened diabetes onset in NOD mice. In addition, no
antioxidant trans gene was found to be able to protect from type 2 diabetes in an Agouti obese diabetic

v

model. But the MT transgene also unexpectedly caused severe diabetes on a normal C57BLIKsJ mouse
which can be made to develop type 2 diabetes by producing obesity and insulin resistance.

The data from this project indicate that the overexpression of antioxidant transgenes protects
cells from ROS damaging stimuli but sensitizes

~-cells

~

to some other insults. Some of these data are at

odds with the long term favored concept that antioxidant treatment is always beneficial for treatment of
diabetes. These results imply that oxidative stress maynot only be harmful, but it may also be necessary to
activate self-protective mechanisms in the

~-cells.
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CHAPTER I
INTRODUCTION

Overview

Diabetes is one of the most prevalent chronic diseases in the world. It is a disease characterized by
high level of blood glucose that results from insufficiency of insulin secretion, or insulin action. Up to now
the etiology of diabetes has not been clearly defined. Previous studies indicate that diabetes is accompanied
by increased production of oxidative stress and shortage of antioxidant defenses in pancreatic beta cells. In
the following text the relevance between diabetes and oxidative stress in pancreatic beta cells will be
discussed. The overall objective of this research, stated in greater detail at the end of this introduction, is to
test whether overproduction of reactive oxygen species (ROS) contributes to beta cell death and diabetes,
and to test whether increased beta cell ROS scavengers could protect from diabetes. To achieve this goal,
transgenic mouse models with beta cell specific expression of antioxidants catalase, manganese superoxide
dismutase or metallothionein were utilized in this study.

Basics of Diabetes

Diabetes mellitus, which literally means "sweet 'excessive urine", is a chronic disease first recognized
by ancient Egyptians almost 2,100 years ago. But until 1922 when Frederick Banting and Charles Best
discovered insulin (Banting & Best 1990), no significant progress was made in understanding and treating
diabetes. Diabetes is a group of metabolic disorders with the common characteristic of hyperglycemia, a
high level of blood glucose. This hyperglycemia results from a deficiency of pancreatic insulin secretion, or
resistance to insulin action, or both. The chronic state of hyperglycemia often leads to a series of late
complications affecting various organs, including kidney, heart, retina, vascular endothelium, as well as
peripheral nerves. In clinics, diabetic patients are diagnosed when they have symptoms of hyperglycemia
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(typically, thirst, polyuria, weight loss, etc), and a plasma glucose level equal to or higher than ILl
mmol/L or a fasting plasma glucose level of at least 7.0 mmol/L (Zimmet et al. 2001).

Diabetes is one of the most prevalent chronic diseases in the world. Currently about 150 million of the
global population is suffering from diabetes. 90% of them are Type 2 diabetes. The World Health
Organization predicts that this number will increase to 220 million in 2010, and 300 million in 2025
(Zimmet et al. 2001). Most of the new cases will be of Type 2 diabetes because current human
environment, human behavior and lifestyle result in more obese people. This explosive increase of diabetic
patients is taking place in both developed and developing countries. In the United States about 8 million
people have been diagnosed with diabetes and 7 million people may have diabetes but they themselves do
not know it. Diabetes has become one of the main threats to human health and imposes a huge burden on
health-care systems. Diabetes is the sixth-leading cause of death by disease in the United States. Unlike
cancer, stroke, and cardiovascular disease, whose death rates declined, the death rate of diabetes increased
about 30% in the past 12 years. On average the United States spends about 105 billion dollars every year in
treatment of diabetes or in diabetes related health care (Olefsky 2001).

Diabetes is generally classified into two major forms: Type 1 diabetes (also called insulin-dependent
diabetes mellitus [IDDM]) and Type 2 diabetes (also called non-insulin dependent diabetes mellitus
[NIDDM]). Type 1 diabetes is primarily due to autoimmune-mediated destruction of pancreatic beta cells,
leading to absolute insulin deficiency. Type 1 diabetes usually occurs in children and young adults. Those
patients would develop diabetic ketoacidosis if not treated with exogenous insulin (Eisenbarth et al. 2003).
Type 2 diabetes is characterized by insulin resistance and abnormal beta cell insulin secretion. Most cases
of Type 2 diabetes are obesity-associated. Patients with Type 2 diabetes, at least initially and often
throughout their life, do not have a need for exogenous insulin therapy. However, if the blood glucose is
not in good control insulin injection might be helpful or required. Type 2 diabetes can often be treated with
diet control, exercise and oral hypoglycaemic medicines (Buse et al. 2003).
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Unfortunately, until now there is still no cure for diabetes despite the many therapies that have been
tried. Although it has been known that both genetic and environmental factors are involved, the real cause
for diabetes is still a mystery. The autoimmune destruction to pancreatic beta cells in Type I diabetes may
be triggered by an interaction between environmental factors (such as a viral infection (Niklasson et al.
2003; Foulis 1996)) and an inherited genetic predisposition of the subjects. In the human genome about 20
different genetic alleles have been found to have some degree of linkage with Type I diabetes (Hawa et al.
2002). But the precise mechanism for how the genetic and environmental factors interact is not completely
elucidated. Type 2 diabetes is a heterogeneous, polygenic disorder. More than one gene is always involved
in an individual patient. But the association between these "identified" genes and Type 2 diabetes is weak
and not always reproducible (Gloyn 2003). The most important environmental factor for Type 2 diabetes is
obesity, which is an important acquired factor contributing to the development of insulin resistance.
However the role of many genetic and environmental factors in Type 2 diabetes is not so well defined.
Recently, extensive studies demonstrated that oxidative stress was significantly increased in both Type I
and Type 2 diabetes. Pancreatic beta cells are extremely sensitive to reactive oxygen species (ROS)
induced damage because beta cells contain relatively low level of ROS detoxifying systems. Therefore we
propose that ROS probably are important mediators causing pancreatic beta cell dysfunction and
destruction during diabetes development.

Reactive oxygen species and Antioxidants
Reactive oxygen species

(ROS) and reactive nitrogen species

(RNS) are oxygen or nitrogen-

containing molecules that have a higher chemical reactivity than ground-state molecular oxygen or nitrogen
(For brevity, in the following text the term ROS is used to indicate both ROS and RNS, unless stated
otherwise). ROS include radicals such as superoxide (02 .-), hydroxyl radical (HO'), nitric oxide ("NO),
and non-radical species such as hydrogen peroxide (H 20 2), and peroxynitrite (ONOO-). Some of these
species, like 02'- and HO', are extremely unstable, while others, like H20 2, are relatively long-lived.

It has been known for a long time that some chemical and physical agents are able to produce ROS.

For example UV light and X-rays induce ROS formation that results in cell damage (Ogawa et at. 2003).
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In biological systems, ROS are generated during the courses of normal aerobic respiration (Lenaz et at.
2002) and normal cellular activities, for example leukocyte mediated cellular disposal processes generate
02

0
-

and H20 2 (lies & Forman 2002). Three main sites of 02

0
-

production have been identified: the

mitochondria, cytochromes on the endoplasmic reticulum, and oxidases located in the cytoplasm and on the
membranes. In the mitochondrial electron transport chain, the NADH dehydrogenase component of
complex I and the ubiquinone Q-cytochrome b component of complex III are believed to be the main sites
of 02

0
-

generation (Freeman & Crapo 1982). When electrons are passed along the complexes of the

mitochondrial electron transport chain 1-3%

(Nohl & Jordan 1986) of electrons "leak" from these

components. Rather than being passed along to the next component of the respiratory chain, some of these
leaked electrons are passed to molecular oxygen to generate 02
greater the production of 02

0
-.

0
-.

The higher the rate of metabolism is, the

A similar phenomenon occurs within the endoplasmic reticulum. Here,

electrons are "leaked" from the NADPH cytochrome P450 oxidoreductase (Aust et at. 1972) and from
cytochrome b5 reductase (Estabrook et al. 1979). A number of cytoplasmic and cell membrane oxidases
are also capable of generating 02

0
-.

Xanthine oxidase (Nishino 1994) and NADPH oxidase (Rossi 1986)

are two of the most significant cytoplasmic and membrane sources of 02

0
-.

NADPH oxidase, first

discovered in the neutrophil, is particularly important in the "oxidative burst" of phagocytic leukocytes
(lies & Forman 2002).

0

Hydrogen peroxide generation is closely linked to the sites of 02 production in the cells. H20 2 may
-

be produced directly from cytoplasmic oxidases such as xanthine oxidase, or from peroxisomal oxidases
(del Rio et at. 1992), or indirectly as a consequence of the enzymatic dismutation of 02

0
-

by superoxide

dismutase. H20 2 itself is weakly reactive. But in the presence of transition metals such as Fe 2+ and Cu 2+,
H20 2 can generate hydroxyl radical (HOO) through Fenton or Haber-Weiss reaction. Iron is present in
biological systems mostly as an essential part of proteins such as hemoglobin, ferritin, cytochromes, Fe-S
proteins, etc.

Hydroxyl radical can rapidly react with any molecules next to it to generate other free

radicals (Harel & Kanner 1988).
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Nitric oxide

("NO) is one of the most important RNS produced under both physiological and

pathological conditions. In eukaryotic cells, nitric oxide is synthesized from L-arginine and molecular
oxygen by one of three nitric oxide synthases (NOS) (Groves & Wang 2000) . Nitric oxide can interact
with other ROS to yield a variety of highly reactive intermediates, including peroxynitrite (Koppenol et al.
1992). Peroxynitrite is a detrimental oxidant produced in activated macrophages, neutriphils and
endothelial cells by a reaction between nitric oxide

("NO) and superoxide

(02

0
-)

(Bartosz 1996;

Koppenol et al. 1992). The overall pathway of ROS production in the living cells is summarized as follows
in Scheme 1.

ONOO"

_ _NOS
_ _-t......

NO"

/

Boca

Scheme 1. Overall pathway of ROS production and enzymatic inactivation.

Despite their essential physiological function in cell signaling, cell proliferation and cellular disposal,
ROS are well known to be toxic and detrimental to cells and tissues. Under certain forms of stress, such as
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UV and virus infection, increased levels ofROS are generated in the cell. Because of their high reactivity,
high level of ROS can induce damage through direct reactions with numerous types of biological
molecules, including proteins, lipids, DNA, RNA, steroids, etc. ROS oxidize proteins causing enzymatic
inactivition (Dmitriev 2001), oxidize lipids leading to cell membrane disintegration (Benderitter et at.
2003), and oxidize DNA resulting in DNA mutation and chromosomal aberrations (Brooks 1997; Dandona

et al. 1996). In addition to their ability to directly inflict macromolecular damage, ROS can function as
signaling molecules to activate a number of cellular sensitive pathways whose activation can also lead to
cellular damage (Forman et al. 2002). In mammalian cells, high levels of ROS mediate the inflammatory
response (Wiseman & Halliwell 1996; McCord 1993). Much evidence indicates that ROS can act as a
mediator of apoptosis

(Buttke & Sandstrom 1994; Jacobson 1996). Excess of ROS may lead to cell

degeneration and death (Aust et al. 1993).

In order to protect against ROS damage to cells, nature has evolved several enzymes and antioxidants
that act in a combined fashion to lower the amount of ROS and ROS induced oxidative damage in the cell.
These antioxidants include a number of small molecular-weight agents, such as glutathione, ascorbic acid,
uric acid, vitamin E, ubiquinones, carotenoids, metallothionein, and others (Aust et al. 1993). Glutathione
(Griffith 1986) is one of the most abundant reductants and acts as a thiol donor converting disulfides to
thiols. It works as a cofactor for glutathione peroxidase (GPx) and glutathione S-transferase. Vitamin E
and ubiquinones exist mainly in biomembranes and function as radical scavengers. Ascorbic acid is also an
abundant biological reductant; it recycles vitamin E in scavenging lipid peroxidation. Uric acid and
carotenoids are presumed to behave as singlet oxygen quenchers and radical scavengers. Metallothionein is
a small protein able to dispose of many ROS including superoxide, hydrogen peroxide, nitric oxide and
peroxynitrite (Cai et al. 2000; Kennedy et al. 1993; Kumari et at. 1998; Sato & Bremner 1993).

The major antioxidant enzymes are superoxide dismutases

(SODs), catalase

(Cat), peroxidases

(such as glutathione peroxidase (GPx) and thioredoxin peroxidase (TPx». SODs (McCord 2002) convert
superoxide to hydrogen peroxide and oxygen. At least three types of SOD have been identified in
eukaryotic cells. Manganese-containing superoxide dismutase (MnSOD) is an 88 kDa tetrameric protein
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that is primarily localized in the mitochondria matrix. MnSOD plays a key role in scavenging superoxide
generated from the electron transport chain. Copper- and zinc-containing SOD (Cu/ZnSOD) is a 32 kDa
dimeric protein that is localized in the cytoplasm. Cu/ZnSOD is thought to remove superoxide generated by
endoplasmic reticulum and cytosolic oxidases. The extracellular SOD (ECSOD) is a 135 kDa tetrameric
protein found in the extracellular space. ECSOD may be important in removing membrane-related oxidasegenerated superoxide. Cat and GPxs convert hydrogen peroxide to water. Cat (Deisseroth & Dounce 1970)
is found in peroxisomes or cytosol. It is a tetrameric protein with large molecular weight of 220 kDa. The
GPxs (Brigelius-Flohe 1999) are a family of selenium-dependent enzymes with a unique t-RNA that
incorporates one atom of selenium per subunit. At least four isoforms of GPx have been described:
cytosolic GPx (GPxl), plasma GPx, phospholipid-hydroperoxide GPx (PHGPx) and gastrointestinal GPx
(GPx-GI). Normal function of all GPx enzymes requires glutathione (GSH) as a cofactor, and secondary
enzymes that include glutathione reductase and glucose-6-phosphate dehydrogenase (G-6-PDH). G-6-PDH
generates NADPH in the pentose phosphate shunt needed by GSH recycling.

When the cells are exposed to different types of stressors, many of those antioxidant enzymes are
highly induced. For examples, metallothionein content in liver, kidney, pancreas and gut can be increased
several fold by interleukin-l ~ during inflammation (Courtade et al. 1998) or after exposure to exogenous
heavy metals (Ohly & Gleichmann 1995; Zimny et al. 1993). SODs and GPx are highly inducible proteins
in a variety of cell types when they are challenged with cytokines (Borg et al. 1992; Strandell et al. 1995),
UV light (Takada et al. 2002), or hypoxia (Yamashita et al. 1994). The increased levels of antioxidants
make the cells more capable of scavenging ROS, thereby diminishing cellular oxidative damage. However,
antioxidant systems are not always enough to scavenge all types of ROS. Under certain circumstance, ROS
detoxifying systems are relatively deficient and oxidative damage occurs, causing cell death and disease. It
has been widely accepted that ROS are involved in many types of disease or biological degeneration
process, such as ischemia/reperfusion injury, cancer, arthritis, and ageing (reviewed in (McCord 1993)).
Diabetes is one of the diseases highly relevant to ROS. Several recent studies found that ROS probably
made a significant contribution to the beta cell death in diabetes (Ihara et al. 1999; Grankvist et al. 1981a).
Following evidence supports this proposition.
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Pancreatic beta cells are extremely susceptible to ROS insults

Compared to other tissues, pancreatic beta cells are extremely vulnerable to the destruction caused by
ROS. This sensitivity has been demonstrated in many in vitro studies exposing pancreatic islets or beta cell
lines directly to ROS. Xanthine oxidase generated superoxide anion (Burkart et al. 1992), nitroprusside
generated nitric oxide (Eizirik et al. 1994a), or hydrogen peroxide (Takasu et al. 1991) inhibit beta cell
insulin secretion, decrease mitochondrial respiration, fragment beta cell DNA and induce beta cell death.
Two widely used diabeteogenic chemicals, alloxan and streptozocin, specifically damage pancreatic beta
cells and induce experimental diabetes in animals (Grankvist et al. 1981a). The action of both compounds
is mediated by ROS including hydrogen peroxide (Takasu et al. 1991), superoxide radicals (Nukatsuka et
al. 1988) and nitric oxide radicals (O'Neill et al. 1993). Some xenobiotic chemicals also cause diabetes in

humans. Intoxication with the rodenticide Vacor (Esposti et al. 1996), an inhibitor ofNADH:ubiquinone
reductase, results in an acute human diabetes. This is probably due to the toxicity of reducing electrons
leaking from the mitochondrial respiratory chain. More than other tissues, pancreatic islets are readily
destroyed by ROS. Cultured rat islets are 2.5 to 25 times more sensitive to peroxide radicals than muscle,
kidney and liver (Malaisse et al. 1982). Beta cell derived HIT and RIN cell lines have much less capacity
to degrade hydrogen peroxide than macrophage like cell lines J-774 cells (Zhang et al. 1995).

This unique sensitivity of beta cell to ROS could be explained either by insufficient ROS detoxifying
systems in beta cells or by presence of a mechanism that allows these ROS related toxins to attack beta
cells more effectively. The beta cell glucose transporter, GLUT2 (Schnedl et al. 1994) is thought to
contribute to the specific toxicity of STZ to beta cells because it can transport STZ. However, many other
tissues, such as liver and kidney that are relatively resistant to STZ, also express GLUT2. In vitro no ROS
accumulation in islet cells was found when islets were exposed to hydrogen peroxide or peroxide radicals
(Zhang et al. 1995; Malaisse et al. 1982). In contrast, the ROS relatively resistant tissues, liver and kidney
contain much higher levels of protective ROS scavengers than beta cells

(Grankvist et al. 1981 b).

Therefore it is logical to extrapolate that a relative deficit of ROS protective systems leads to the striking
sensitivity of beta cells to the destruction by ROS.
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Direct analysis of ROS scavengers reveals that pancreatic beta cells are short of ROS detoxifying
systems. The level of three most important enzymatic antioxidants, superoxide dismutases

(SODs),

glutathione peroxidase, and catalase is extremely low in beta cells. Grankvist et al (Grankvist et at. 1981 b)
reported that total islet SOD level was less than 30% of that measured in liver. The levels of glutathione
peroxidase and catalase in islets were as low as less than 2% of liver and among the lowest of all tissues
assayed (Malaisse et at. 1982; Grankvist et al. 1981b; Johansson & Borg 1988; Welsh et at. 1995).
Therefore the inherent inadequacy of ROS detoxifying systems in beta cells makes themselves particularly
vulnerable to ROS damage. Any elevation of antioxidant levels specifically in beta cells is projected to
provide protection against ROS destruction to the pancreatic beta cells.

Involvement o(ROS in autoimmune Tvpe 1 diabetes
Type 1 diabetes is an autoimmune disease characterized by the selective destruction of beta cells
within the islets of Langerhans (Bach 1994). This destruction is a complex process involving beta cell
antigen autoantibodies generated by B lymphocytes, inflammatory cell infiltration (termed insulitis) and
cytokine release (Eizirik et al. 1996; Bach 1994; Oberley 1988; Horio et at. 1994). ROS participate in
these processes leading to beta cell destruction through the oxidation of nucleic acids, proteins and
membrane lipids (Gutteridge & Halliwell 1990; Wiseman & Halliwell 1996; Halliwell & Gutteridge
1995).
During autoimmune attack, ROS are generated by activated macrophages (Nathan 1987) and by beta
cells themselves in response to cytokines (Rabinovitch et al. 1992). The cytotoxic effect of activated
marcophage is thought to initiate early damage on beta cells through the action of ROS. In non-obese
diabetic (NOD) mouse model of Type 1 diabetes, hydrogen peroxide was found markedly increased in
isolated islets co-cultured with macrophage-enriched fractions

(Horio et al. 1994). The antioxidant

probucol can reverse the elevation of hydrogen peroxide, thereby providing a significant protection against
cyclophosphamide speeded diabetes in NOD mice (Fukuda et al. 1995). Upregulation of ROS release is
also found in macrophages from autoimmune diabetes prone BB rats (Brenner et al. 1993). Apart from
direct cytotoxicity by macrophages and T-lymphocytes (Nagata & Yoon 1992), cytokines secreted from
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these cells such as interleukin I-beta

(IL-l~),

tumor necrosis factor-alpha (TNF-a) and interferon-gamma

(IFN-y), cause a broad spectrum of damaging events ranging from an inhibition of beta cell function up to
beta cell death through necrosis and apoptosis (Eizirik et al. 1996; Rabinovitch & Suarez-Pinzon 1998).
ROS are also involved in these destructive events. Reactive oxygen intermediates were indicated to be
produced in both cultured human islets (Rabinovitch et af. 1996) and rat islets (Rabinovitch et af. 1992)
after treatment with combined cytokines

IL-l~,

TNF-a and IFN-y. Nitric oxide (NO), which is generated

in beta cells through the activation of inducible NO synthase (iNOS) gene, is one of the most important
mediators for cytokine induced beta cell toxicity (Corbett et af. 1993; Flodstrom et al. 1999). NO can react
with superoxide to produce highly reactive and toxic peroxynitrite that is found in beta cells of diabetic
NOD mice (Suarez-Pinzon et af. 2001; Suarez-Pinzon et al. 1997). Mice whose iNOS gene has been
knocked out are highly resistant to autoimmune diabetes generated by multiple low doses of streptozotocin
(Flodstrom et al. 1999).

Since ROS are so essential in autoimmune diabetes, many trials using antioxidants to treat diabetes
and prevent beta cell damage have been performed. Non-enzymatic chemicals with antioxidant properties,
including vitamin E (Behrens et af. 1986), probucol (Shimizu et al. 1991; Drash et al. 1988), MDL 29,311
(Heineke et af. 1993), and lazaroid (Rabinovitch et al. 1993), have been tested in various rodent Type 1
diabetes models including the NOD mouse, the Bio-Breeding (BB) rat, and the low dose STZ model. The
results revealed that antioxidant treatment was beneficial to preventing diabetes. More current studies were
carried out to examine the potential role of antioxidant proteins SOD, catalase and glutathione peroxidase.
These enzymes were either administrated using a carrier or overexpressed in the beta cell lines by gene
transfer technologies. Horio et al (Horio et al. 1994) reported that in vivo administration of catalase or
SOD coupled to polyethylene glycol reduced islet damage in the NOD models of diabetes. In insulinproducing tumor cell lines catalase and glutathione peroxidase have been shown to have protective effects.
Overexpression of catalase or glutathione peroxidase in beta cell-like RINm5F cells provided protection
from hydrogen peroxide, superoxide anion and NO

(Tiedge et af. 1997). But the effect of SOD is

inconsistent. In one beta cell line, INS-l cells, MnSOD overexpression completely protected from IL-l ~
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mediated cytotoxicity through the inhibition of iNOS activation (Hohmeier et al. 1998). However, single
overexpression ofCu/Zn SOD in RINm5F cells either had no effect on the toxicity of hydrogen peroxide or
even increased the toxicity, while co-expression of SOD and catalase provided protective effect on
RINm5F cells

(Tiedge et al. 1998). This indicates that SOD action may differ in different cellular

situations and its proper action may need catalase complementation. A recent study by Lortz et al (Lortz et
al. 2000) reported that overexpression of antioxidant proteins Cu/Zn SOD, catalase and glutathione
peroxidase in RINm5F cells significantly increased the resistance to cytokines through inactivation of ROS
generation rather than through reduction of NO generation. Moreover, a recent in vivo study by Hotta et al
(Hotta et al. 1998) strongly supported antioxidant therapy benefited NOD diabetes. In their study an
antioxidant protein thioredoxin was overexpressed specifically in beta cells of NOD mouse. With this
overexpression, the incidence of diabetes in NOD mice was markedly reduced. Therefore, these data,
particularly in cultured beta cell lines suggest an important role of ROS contributing to beta cell death
during Type 1 diabetes and a potential therapeutic value of antioxidants in treatment of Type I diabetes.

However some studies failed to observe any protective effect by ROS scavengers. Burkhart (Burkart
& Kolb 1993) et al reported that SOD, catalase, and antioxidant compounds citiolone and dimethyl-

thiourea did not improve the viability of cultured islets damaged by activated macrophage. Welsh et al
(Welsh et al. 1994c) tested liposome delivered SOD, catalase and gluthathione peroxidase against IL-1 ~
induced beta cell toxicity. Their results were also negative. Hence, uncertainty about the role of ROS in
Type 1 diabetes still remains. But unlike the study of Hotta et al. (Hotta et al. 1998) where thioredoxin was
uniquely expressed in beta cells at a higher level in a permanent fashion, the antioxidant application
assisted by glycerol or liposome is neither permanent nor targeted to the beta cells. The success of
thioredoxin implies that antioxidant treatment against Type 1 diabetes may require an early startup and a
specific action on beta cells for a long time. On the other hand, the conclusion from thioredoxin study can
still be criticized in that thioredoxin has other functions other than being an antioxidant (Hirota et al. 1999;
Nakamura et al. 1997). Therefore in this project we used more specific antioxidants MnSOD and catalase
to investigate the role ofROS in Type I diabetes.
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Involvement o(ROS in Tvpe 2 diabetes
Type 2 diabetes is characterized by both insulin resistance and pancreatic beta cell dysfunction.
During the development of Type 2 diabetes, the normal insulin secretion of beta cells is impaired and beta
cells may eventually undergo degeneration. Recent evidence suggests that ROS play an important
pathological role in degeneration of the beta cells in Type II diabetes. The presence of ROS leads to
abnormal cell function or cell death because ROS oxidize cellular DNA, protein and lipid to nonfunctional
derivates such as 8-hydroxydeoxyguanosine

(8-0HDG), 3-nitrotyrosine, malondialdehyde

(MDA)

(reviewed in (Rosen et at. 2001). These oxidized products have been widely used as biomarkers to indicate
the oxidative damage caused by ROS. It has been demonstrated that these biomarkers are significantly
enhanced in urine (Dandona et al. 1996) and plasma samples (Gopaul et at. 1995) from Type 2 diabetes
patients.

Direct evidence showing oxidative damage

present in beta cells

comes

from

an

immunohistochemistry studies (Ihara et al. 1999) in Goto-Kakizaki (GK) rat, a model of Type 2 diabetes.
In this diabetic rat the beta cells had very high levels of 8-0HDG and 4-hydroxy-nonenal (HNE) modified
proteins, while in nondiabetic control animals these two markers were virtually undetectable. The level of
oxidative damage indicated by these two markers corresponded to the severity of diabetes.
Supplementation of antioxidant vitamin E to GK rats revealed an accumulation of vitamin E in pancreas
and improvements of glucose tolerance and diabetic control (Ihara et al. 2000).

The source of oxidative stress to the beta cells in Type 2 diabetes is not as clear as that in Type I
diabetes. Chronic hyperglycemia or long-chain fatty acid deposition in beta cells may both be involved in
ROS generation (Hayden & Tyagi 2002). Under diabetic conditions with high concentrations of glucose,
ROS release and resultant beta cell destruction have been proven in a variety of studies. Kaneto et al
(Kaneto et at. 1996) reported that culture of a beta cell line, HIT-TIS cells, in high glucose medium raised
cellular levels of hydrogen peroxide and malondialdehyde. When antioxidant N-acetyl-L-cysteine (NAC)
or aminoguanidine (AG) was added to the culture medium, the high glucose induced decrements of insulin
mRNA, insulin gene promoter activity, DNA binding activity of insulin promoter transcription factors
PDX-l and RIPE-3bl, as well as the loss of insulin content and secretion in HIT-TIS cells were all
significantly reduced

(Tanaka et at. 1999a). In vivo application of these two antioxidants to Zucker
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diabetic fatty rats, a model of Type 2 diabetes, reduced the elevation of oxidative stress markers, improved
insulin secretion and prevented the development of glucose intolerance (Tanaka et al. 1999a). In another
Type 2 diabetes animal model, db/db mice, chronic treatment with NAC or antioxidant vitamins E or C
reduced beta cell mass loss, maintained beta cell insulin content and improved glucose tolerance (Kaneto

et at. 1996).

The mechanism of ROS generation in beta cells exposed to high glucose is still not completely
elucidated. Many studies have emphasized the essential roles of ROS in the development of diabetic
complications in heart, neurons and kidney after long term exposure to hyperglycemia (Nishikawa et al.
2000). The mechanism for hyperglycemia induced ROS production in tissues other than pancreatic islets
may also apply to beta cells. Hyperglycemia can increase the levels of ROS through non-enzymatic
glycosylation, glucose autoxidation and the polyol pathway (Nishikawa et al. 2000). In non-enzymatic
glycosylation, glucose initially undergoes a nucleophilic addition reaction with proteins to form a Schiff
base, forming early glycosylation products that are reversible when blood glucose level returns to normal.
However, the early products may form Amadori compounds, a process that can form H20 2 in vitro.
Amadori products can generate H20 2 via two pathways. One pathway is the 1,2-enolization pathway,
which generates H20 2 and glucosone under anaerobic conditions. The other pathway, the main pathway to
produce H2 0 2 under oxidative conditions, is 2,3-enolization pathway that forms I-deoxyglucosone and the
putative 1,4-deoxyglucosone. Further reactions of Amadori compounds result in polymerization of proteins
by forming insoluble, irreversible crosslinking complexes called advanced glycosylation end-products
(AGEs). AGEs tend to accumulate on long-lived macromolecules in tissues, leading to abnormalities of
cell and tissue functions.

In addition to direct glycosylation reactions, monosaccharides and fructose-lysine can spontaneously
reduce molecular oxygen under physiological conditions. This process is called glucose autoxidation which
is able to produce oxidizing intermediates, such as 0 2

0
-

,

'OH and H2 0 2 , and alpha-ketoaldeydes. Those

ROS can not only damage lipids and proteins, but also accelerate the formation of AGEs, which in tum
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produce more ROS. Some metal chelating agents that prevent autoxidation have been shown to protect
from experimental diabetes in animals (Nakamura et al. 2002).

ROS can also be generated via polyol/sorbitol pathway. Exposure to elevated glucose levels increase
intracellular sorbitol and fructose content due to aldose reductase and sorbitol dehydrogenase activity.
Oxidation of sorbitol to fructose is coupled to reduction of NADP+ to NADPH at the expense of NADH.
An increase in NAD+!NADH ratio is linked to O2'- formation via the reduction of prostaglandin G2
(PGG 2) to prostaglandin H2 (PGH 2) by prostaglandin hydroperoxidase (Minegishi et al. 2002).

Hyperglycemia and hyperlipidemia usually occur together in Type 2 diabetes. Elevated free fatty
acids (FF As) not only induce a state of insulin resistance (Paolisso et al. 1995), but also impair beta cell
function (Bollheimer et al. 1998; Zhou & Grill 1994). There is also evidence that FF As may cause beta
cell death (Lee et al. 1997; Shimabukuro et al. 1998a). The toxicity ofFFAs may be mediated by nitric
oxide and/or ceramide. Shimabukuro et al (Shimabukuro et al. 1997) demonstrated that FF As significantly
induced NO production through the activation of iNOS gene in cultured islets from ZDF rats. Treatment
with antioxidants nicotinamide or aminoguaunidine improved the insulin secretion that was inhibited by
FF As. In vivo both compounds had the effects on preventing beta cell destruction and hyperglycemia.
Shimabukuro et al also reported that apoptosis was increased in islets of ZDF rat (Shimabukuro et al.
1998a) accompanied by an excessive production of NO and ceramide

(Shimabukuro et al. 1998b;

Shimabukuro et al. 1998a). The elevated ceramide results from de novo synthesis from unoxidized FFA
deposits in beta cells. ROS may be released from mitochondria upon ceramide action, in that ceramide can
regulate the permeability of the mitochrondial membrane and activity of respiratory complex III (reviewed
in (Mathias et al. 1998». A recent study (Listenberger et al. 2001) supported a direct involvement ofROS
in lipotoxic response although it did not involve ceramide. In this study Chinese hamster ovary (CHO)
cells were exposed to saturated fatty acid palmitate. It was found that palmitate induced apoptosis through
the generation of ROS detected by an oxidant-sensitive fluorescent probe. Antioxidants pyrolidine
dithiocarbamate and 4,5-dihydroxy-l,3-benzene-disulfonic acid both blocked palmitate-induced caspase
activation and DNA laddering. However, another recent report totally excluded NO or other ROS effects
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on beta cell death caused by FFAs (Cnop et al. 2001). When isolated normal Wistar rat islets were exposed
to increasing concentrations of palmitate or oleate, both apoptosis and necrosis were induced. The
cytotoxicity of FFAs was dose dependent. Nevertheless, neither iNOS mRNA increase nor NO formation
was detectable and therefore did not contribute to the FFA toxicity. The application of antioxidants
including nicotinamide, SOD or mixtures of vitamin A, C, E, dithiothreitol and glutathione could not
reverse the cytotoxicity of FF As. In contrast to the previous studies using diabetic or prediabetic ZDF rats
or their islets, the islets used in that study are normal Wistar rat islets. Normal islets may behave differently
in response to FF As since they probably have sufficient and/or normal cellular mechanisms to prevent FF A
induced cell death. All these result indicate that ROS may contribute to the beta cell destruction in Type 2
diabetes, however the roles and mechanisms ofROS in Type 2 diabetes warrant further investigation.

Hvpotheses
Substantial evidence supports the concept that pancreatic beta cells are extremely vulnerable to ROS
damage and ROS are involved in both Type 1 and Type 2 diabetes. Therefore, we hypothesize that the
deficit of ROS detoxifying systems in pancreatic beta cells significantly contributes to beta cell
pathology and that enhanced ROS protection will reduce beta cell destruction caused by ROS and
thereby prevent experimental diabetes.

Despite extensive studies, it is still uncertain what roles ROS play in the diabetes because most of the
evidence can be criticized for limitations in experimental approach: (l) Most ROS scavengers that have
been used have actions other than ROS protection. For example, the antioxidant probucol inhibits
macrophage function in addition to being an antioxidant (Kita et al. 1987). The most promising agent
thioredoxin used in the study by Hotta et al (Hotta et al. 1998) could have additional effects such as antiapoptosis rather than antioxidant only. (2) Enzymatic antioxidants, such as catalase and SOD, do not enter
the beta cells as freely as small molecule chemical antioxidants. Consequently exogenous administration of
these antioxidant proteins usually has low efficacy. (3) In vitro studies oversimplify diabetes and may not
extrapolate to the whole animals. (4) Apart from the action on beta cells, ROS scavengers applied in vivo
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may have actions on other sites such as the immune system, liver or lipid metabolism, or other systems
(Jialal et al. 2002; Venugopal et al. 2002), which confounds the interpretation of the results. (5) Also, in
some situations the application of ROS scavengers in vivo does not always prevent diabetes. Eliminating
these limitations as much as possible is necessary for a clear test of the role ofROS in diabetes. To exclude
these uncertainties in this study we used transgenic mouse models. In these transgenic animals, three
different types of antioxidant proteins catalase, MnSOD or MT were expressed uniquely in the beta cell at
high and stable levels starting at the birth of animals. These antioxidant proteins are able to scavenge many
types of ROS.

Hence this in vivo system provided an optimal model for investigation of the ROS

hypothesis.

The following specific aims were carried in this study to test this hypothesis.
(1)

Determined whether elevated catalase, MnSOD, MnSOD plus catalase or MT provided

protection against beta cell toxins. Transgenic islets or mice were tested for resistance to streptozotocin,
superoxide anion, hydrogen peroxide, peroxynitrite and nitric oxide.
(2)

Determined whether these elevated antioxidant proteins provided protection against immune

attack related to Type 1 diabetes. Transgenes were tested for protective effects against cytotoxicity in islets
exposed to combined interleukin-l p and interferon-y, and against diabetes in the NOD mouse model of
Type 1 diabetes.
(3)

Determined whether these elevated antioxidant proteins prevented oxidative damage and

preserved beta cell function in states of Type 2 diabetes. Transgenes were tested for protective effects in
obese agouti mice, a model of Type 2 diabetes.
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CHAPTER II
GENERATION AND EVALVA TION OF TRANSGENIC MICE WITH PANCREATIC BETA
CELL SPECIFIC OVEREXPRESSION OF ANTIOXIDANT PROTEINS

Introduction
The first successful transgenic animal was a transgenic mouse created in 1980 (Gordon et al. 1980).
Since then, huge amounts of transgenic animals have been generated with incredible speed of advancement
for biomedical research. But to date transgenic mice are still the most popular animals in transgenic
research. Several factors may account for this popularity. One reason is that the mouse is easy to
manipulate and maintain in the laboratory. The other reason is that the genetic structure and physiological
systems of mouse and human are quite similar. Scientists already have a solid understanding of the mouse
genome, embryology and physiology in that mouse has been used as an animal model for biomedical
research for more than 100 years. Therefore the generation and manipulation of transgenic mice for
researchers is readily accessible; the assessment and interpretation of data from transgenic mice is easier to
obtain and as informative, accurate and reliable as that from rats and other types of animals (Boyd &
Samid 1993; Hammer et al. 1985).

A transgenic animal is an animal whose genome has been artificially modified in order to study the
potential function of the modified gene (or genes) of interest. The creation of transgenic animals involves a
transfer of a genetically engineered segment of foreign gene (or genes) into the genetic material of the
animal. This introduced foreign gene is called transgene. When the transgene is integrated into the host
genome, it is stable to be transmitted through the germ line to the offspring. Currently there are at least
three basic methods to produce transgenic animals, which are DNA microinjection, retrovirus mediated
gene transfer and embryonic stem cell mediated gene targeting. In this project we produced transgenic
animals by DNA microinjection procedure. In this method the transgene was first constructed in a genetic
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carrier (commonly a plasmid) by aligning a segment of DNA sequence (gene of interest) within several
regulatory elements, including tissue specific promoter, enhancer and poly A tail. The constructed
trans gene was then microinjected with a very fine needle into the pronucleus of a one cell mouse embryo.
These microinjected embryos were implanted into the oviduct of pseudopregnant mice. Progenitor mice
were born with the trans gene three weeks later. Then the transgenic mice were identified and maintained by
subsequent cross-breeding (Gordon 1993).

Nowadays, transgenic animals have become a very valuable tool for biomedical research and
pharmaceutical product development. They have made a great contribution to research for human welfare,
such as xenotransplantation (Zhou et al. 2002; Vial et al. 2000), supplementation of nutrition (Wheeler et
al. 2001) and pharmaceutical products

(Kadokawa et al. 2003). But more commonly the transgenic

animals are utilized as animal models for human diseases, thereby helping scientists in discovering etiology
and pathology of the diseases, and improving the therapeutics of those diseases (Yamamura et

at.

1992;

Ishiguro et al. 2001). The advantage of using transgenic animals in this field is clear-cut. Since the
trans gene is integrated into host genome, the expression of the transgene is stable and heritable. This long
term and stable expression is clearly suitable for many chronic disease studies. Since the transgene is
expressed in a truly in vivo state, the interaction of trans gene with proteins, hormones, neurotransmitters,
and other components of the animals provides a much more complete and physiologically relevant picture
of the transgene's function than could be achieved in any other way, for example in cultured cells. With
tissue specific promoters, transgenes may be specifically expressed in certain types of cells or organs. This
confined expression pattern allows a clear-cut test of the potential of the trans gene in a specific organ or a
specific biological process. The economic value of transgenic animal is also significant. Compared with
some other classic research techniques, using transgenic animals often significantly reduces the number of
required animals and the time for studies (Contrera & DeGeorge 1998; Jegstrup et al. 2003).

Many transgenic mice with beta cell specific expression of foreign genes have been produced. In
those animals pancreatic beta cells have overexpressed genes for anti-apoptotic proteins (Liu et al. 1996),
growth factors (Hoeflich et al. 1999), transcription factors (Welsh et al. 2002; Flodstrom & Eizirik 1997;
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Dutta et af. 2001), ion channels (Koster et af. 2000), or metabolic enzymes (Epstein et af. 1992), etc.
These transgenic animals have provided a profound knowledge about beta cell development, physiology,
and diabetes pathology and therapeutics. However few transgenic mice with beta cell overexpression of
antioxidant transgenes have been generated. Apart from the models in our laboratory, Cu/Zn SOD has been
expressed in beta cells and shown to protect from alloxan induced diabetes

(Kubisch et af. 1997).

Thioredoxin, which actually has multiple functions; including being an anti-apoptotic protein and an
antioxidant protein, was found to prevent NOD diabetes and STZ induced diabetes by specific expression
in pancreatic beta cells (Hotta et af. 1998). But transgenic overexpression of extracellular SOD in beta
cells failed to prevent NOD diabetes (Sandstrom et af. 2002). The concept that antioxidants are effective to
protect beta cell against damage in diabetes is mostly based on in vitro studies carried on insulin secreting
cell lines and isolated islets (Tiedge et af. 1998; Tiedge et al. 1999; Hohmeier et al. 1998). Therefore the
proof of this concept awaits further in vivo evidence.

To carry out these in vivo studies, we produced lines of transgenic FVB mice with elevated expression
of antioxidant proteins: rat catalase, human MnSOD, and human MT. These antioxidants were expressed
specifically in pancreatic beta cells regulated by the insulin promoter. Both Type 1 (NOD mice) and Type
2 diabetes (Agouti mice) animal models with beta cell specific expression of those antioxidants were also
developed by continuous back-crossing or cross-breeding. By using those transgenic mice we have tested
whether direct antioxidant protection of pancreatic beta cells provides protection against oxidative damage
to pancreatic beta cells and against Type 1 and Type 2 diabetes.
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Materials and Methods
Chemicals: Collagenase (type V), Histopaque 1077, purified bovine erythrocyte SOD and rat liver
metallothionein were obtained from Sigma (St. Louis, MO). Hank's balanced salt solution (HBSS), RPMI
1640 medium, fetal bovine serum (FBS) and PCR reaction reagents

(including Platinum Taq DNA

polymerase, dNTP, Tris PCR buffer and MgCI 2) were supplied by Invitrogen (Carlsbad, CA). Proteinase
K was purchased from Qiagen (Valencia, CA) and

I09 cadmium

was from Amersham (Piscataway, NJ).

Rat insulin standard was bought from Linco (St. Charles, MO). Rabbit antiserum to guinea pig insulin,
was purchased from BioGenex (San Ramon, CA). Mouse anti-horse MT antibody was supplied by Dako
(Carpinteria, CA). Sheep anti-human SOD antibody was bought from Biodesign International

(Saco,

Maine). For construction of the transgene enzymes were obtained from New England Biolabs (Beverly,
MA). Other non-indicated reagents were standard chemicals from Sigma (St. Louis, MO), Fisher Scientific
(Pittsburgh, PA) or Amersham Biosciences (Piscataway, NJ).

Solutions: The following solutions, very commonly used in this project, will not be further described
wherever they were used. They are islet culture medium (with or without phenol red) (RPMI 1640
medium supplemented with 10 % fetal bovine serum plus 100 U/ml penicillin and 100 f..lg/ml
streptomycin), modified KRB buffer

(Krebs-Ringer bicarbonate buffer, containing the designated

concentration of glucose and supplemented with 0.1 % BSA and lOmM Hepes, pH 7.4), islet sonication
buffer (10mM TrislHCI, pH 7.0, ImM EDTA, Img/ml RIA grade BSA,), acid ethanol for islet insulin
extraction (75 ethanol I 2 concentrated (12 M) HCI 123 H20, v/v/v), islet DNA digestion buffer (O.IM
Tris/HCI, pH 8.5, 5 mM EDT A, 0.2 % SDS, 200 f..lglml proteinase K), Tris-acetate-EDTA (T AE) buffer
for electrophoresis (0.04 M TrislHCI, 0.001 M EDTA, pH 8.5).

Animals: The transgenic mice were generated on FVB strain which was purchased from Jackson
Laboratory (Bar Harbor, Maine). Transgenic mice were maintained by cross-breeding with plain FVB
mice. The presence of trans genes was determined by peR of mouse tail DNA and/or by observation of coat
color which was a product from a co-injected second transgene tyrosinase. All mice were housed in
ventilating cages at the University of Louisville, Reseach Resource Center with free access to tap water and
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standard mouse chow. All animal procedures were approved by the Institutional Animal Care and Use
Committee. The laboratory was certified by the American Association of Accreditation for Laboratory
Animal Care.

Transgene constructs and establishment of transgenic mice: Figure 2-1 is a simplified scheme
showing the construct of our antioxidant trans genes. The antioxidant gene was regulated with a rat or
human insulin promoter, which allowed the antioxidant protein to express specifically in pancreatic beta
cells. An SV -40 enhancer sequence was placed in the downstream portion of the antioxidant gene for an
efficient expression in the target tissues. These transgenes were constructed in specific plasm ids as
described below. To generate transgenic mice, the transgenes were removed from the plasmid sequences by
cutting with specific restriction enzymes and microinjected into FVB mouse embryos. A second transgene
containing a cDNA for the enzyme tyrosinase was co-injected with the antioxidant trans gene. The enzyme
tyrosinase produces coat color pigmentation in albino mice (Brooks 1997) such as FVB and NOD mice.
This pigmentation helps to conveniently identify transgenic animals. The embryos injected with trans genes
were transferred back into the womb of pseudopregnant FVB female mice to produce offspring. From
those offspring, the transgenic progenitors were established by determining the presence of the trans genes
using PCR of the tail DNA. Cross-breeding between these progenitors and plain FVB mice was carried out
to maintain and expand the colonies. Transgenic mice were further assessed by immunohistochemistry and
antioxidant protein activity assays for assessing the expression activity of trans genes.

In more detail, the MT transgene, designated HMT, was constructed utilizing the plasmid INS.HBS
provided by Dr. Timothy Stewart (Genentech, California). This plasmid contained the human insulin
promoter and first intron followed by unique BamH I and Hind III sites. A 2.4 kb Nco I / Hind III
fragment containing all introns and exons of the human MT II gene was ligated behind the insulin promoter
utilizing the BamH I and Hind III sites ofINS.HBS. Prior to ligation the Nco I and BamH I sites were blunt
ended with Klenow polymerase. Before microinjection, the 4100 bp HMT trans gene was removed from
plasmid sequences by cutting with Hind III and EcoR!.
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The catalase transgene, designated Cat, was constructed in a plamsid pKS/RlP provided by Dr.
Fatima Bosch (Barcelona, Spain) as described previously (Xu et al. 1999). This gene contained the rat
insulin I promoter linked to 1.8 kb BamHIlXho I fragment of the rabbit beta globin gene that included the
last beta globin intron and the globin polyadenylation sequence. An SV -40 enhancer sequence was
contained in the downstream portion of the gene. The catalase cDNA was inserted into a unique Eco Rl site
of pKS/RlP located 45 bp downstream from the rabbit beta globin intron. The rat catalase cDNA contained
the entire 1581 bp catalse coding sequence and was cleaved from the trans gene MyCat (Kang et al. 1996)
with Sal I and Hind III. The termini of the catalase fragment were converted to Eco Rl sites by blunt ending
and ligation to Eco Rllinkers. The 4250 bp transgene was removed from the plasmid sequences by cutting
with Xho I and Sac I. The MnSOD transgene, designated as MnSOD, was constructed in the same plasmid
pKS/RlP by replacing the catalase cDNA with a full length human MnSOD cDNA.

peR typing of transgenes: To determine the presence of transgenes, mouse tail DNA was extracted

with Qiagen DNAeasy kit (Qiagen, Valencia, CA) according to the manufacturer instructional manual.
PCR reaction was performed in a 20 ).tl volume containing 1.5 ).tl sample DNA (about 20 ng DNA), 200
).tM dNTP, I).tM of each primer, 0.8 unit of Platinum Taq DNA polymerase, 2 mM MgCh and 10mM Tris
I x PCR buffer (Invitrogen, Carlsbad, CA). PCR reaction was carried out in an Eppendorf thermocycler
equipped with a heated hood. The reaction contained a first polymerase activation step at 95°C for 2 min,
followed with 35 cycles of amplification, and ended with an extension step at

noc

for 7 min. Each

amplification cycle consisted of I min of denaturing at 94°C, I min of annealing at 57°C and I min of
extension at

noc. PCR products were fractionated on 0.9% agarose gel in TAE electrophoresis buffer and

stained with 0.5 ).tglml ethidium bromide. The sequences for each set of primers for each trans gene were as
follows: MnSOD (forward 5' -GGATCCTGAGAACTTCAG-3', reverse 5'-TTCTGCCTGGAGCCCAGAT
AC-3'); Catalase (forward 5'-AATATCGTGGGTGACCTCAA-3', reverse 5'-GGATCCTGAGAACTTC
AG-3'); MT (forward 5'-AATCGGTTGTGGACTGAGGA-3', reverse 5'-CCTGATAAGATCACTGAG
GA-3'). In addition to the primers for transgene, another set of primers (forward 5'-CTGGTGATGGCTT
CCTTG-3', reverse 5'- CTCAATGTTGAGCAGGAA-3') was included in every PCR reaction in order to
monitor the quality of DNA sample and PCR reaction. This pair of primers was used to identify heme
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oxygenase which is ubiquitously expressed in all strains of our mice. At each time control PCR reactions
for transgene positive and negative DNA were also performed.

Islet isolation: The isolation procedure was based on a modification of the method of Gotoh et al

(Gotoh et al. 1985). Mice were anesthetized with avertin at the dose of 6 mg/g body weight via
intraperitoneal injection. The pancreas was inflated with 3 ml of 1.55 mg/ml collagenase Type V, and
carefully removed from the mouse body and incubated at 37°C for 20 min. Digestion was stopped by
adding cold HBSS followed by vigorous shaking and 3 washes in 50 ml cold HBSS and passage through a
200 !lm mesh. The final pancreas pellet was resuspended in 10 mL Histopaque 1077, overlaid with 10 ml
of HBSS and centrifuged at 700x g for 20 min at 10°C. Most of the gradient, excluding the pellet was
collected and washed twice with cold HBSS. Islets were then handpicked and maintained in islet culture
medium at 37°C and 5 % CO 2 plus humid air. Islets were normally be used the day after isolation. For
experiments requiring extended culture, medium was changed every two days.

Immunohistochemistry for insulin, MT and MnSOD: Transgenic or control mouse pancreas was

fixed in 10% formaldehyde in 0.1 M phosphate buffer (pH 7.2), dehydrated in an ascending graded series
of ethanol and subsequently infiltrated with paraffin.

Serial sections were cut at 5!lm, mounted on

poly lysine coated slides and then rehydrated in a descending graded series of ethanol. Slides were treated
with 3% hydrogen peroxide followed by an additional 10 min incubation with Power Block (Biogenex).
Sections were treated with primary antibody (rabbit anti-guinea pig insulin antibody diluted 1 to 100 or
mouse anti-horse MT and sheep anti-human SOD antibodies at a 1:50 dilution).

Primary antibody

incubations were 90 min at 37°C. After 4 washes in phosphate buffered saline slides were incubated with
the appropriate biotin-labeled second antibody followed by peroxidase labeled streptavidin and developed
with 3-amino-ethyicarbazone

(AEC) as chromagen.

On some sections the primary antibodies were

omitted or replaced with non-immune sera of the appropriate species. Those sections always demonstrated
negligible levels of staining.
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Measurement of islet MT content. Islet metallothionein content was determined by Cadmium-Chelex
assay (Bartsch et at. 1990). After an overnight incubation, 100 to 150 islets were rinsed 3 times with
HBSS and then sonicated in 150 III 10 mM Tris HCl, 85 mM NaCl, pH 7.4 for 1 minute on ice. After 30
minutes of centrifugation at 20,000 x g at 4°C, 100 III of the supernatant was incubated with 100 III
acetonitrile for 3 min at room temperature. One ml of 10 mM Tris HCl, 85 mM NaCl, pH 7.4 was added to
the mixture. The solution was then incubated with 10 III of 1 mM CdCh containing 740 kBq/ml 109Cd for 5
min at room temperature. Chelex binding was carried out on a shaker for 15 min after adding 100 III
Chelex suspension (66 % v/v in 10 mM Tris HCl, 85 mM NaCl, pH 7.4). The resin and precipitate were
removed by centrifugation at 12,000 x g for 5 min, and the supernatant fraction was analyzed for 109Cd
with a Beckman gamma counter. Metallothionein concentrations were determined from a standard curve of
purified rat liver metallothionein (Sigma). Values were expressed per Ilg of islet protein in the sonicate,
determined with the Pierce BCA protein assay.

Measurement of SOD activity in isolated islets. Islet SOD activity was measured by inhibition of
the autooxidation of pyrogallol (Marklund & Marklund 1974). Two hundred frozen islets were sonicated
in

250

III

of

prechilled

assay

buffer

(50mM

Tris-cacodylic

acid,

pH

8.2,

ImM

diethylenetriamineeprentaacetic acid) for 1 min on ice. After solubilization for 30 min on ice, the sonicate
was centrifuged at 20,000x g for 30 min. The supernatant was used to determine islet SOD activity
performed in a 96-well plate. In each well 50 III of the supernatant was mixed with 175 III of assay buffer,
followed by a quick addition of 25 Ill, 2 mM pyragallol dissolved in 10 mM HC!. After reaction for 2 min,
the absorbance increasing rate of each well was read in a microplate reader at the wavelength of 405 nm for
2 min at a 10-second interval. SOD activity was determined from a standard curve obtained with purified
bovine erythrocyte SOD (Sigma). Values were expressed per mg of islet protein in the sonicate, determined
with the Pierce BCA protein assay.

Measurement of catalase activity in isolated islets. The assay for islet catalase activity was carried
out by Bo Xu (Xu et al. 1999) based on a peroxidatic procedure of (Johansson & Borg 1988). Briefly 100
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islets were homogenized in 100 III of 25 mM KH 2P0 4, pH 7.0 by sonication. Twenty microliters of this
extract was added to a reaction mixture containing 45% methanol, 0.025% H20 2 as the substrate of
catalase. After the reaction was stopped by 7.8M KOH, the chromogen purpald (34 mM, Sigma) was
added to develop colorized product which was further oxidized and stabilized by addition of KI0 4. The
final absorbance of each vial was measured at the wavelength of 550 nm. The islet catalase activity was
calculated from a standard curve of purified bovine catalase (Sigma) and expressed as equivalent milliunits
of that bovine catalase per islet.

Assays for insulin secretion, insulin content and DNA content. Glucose stimulated islet insulin
secretion was measured by static assay on 96-well tissue-culture microplates. For each well 6-10 islets
were hand picked into modified KRB buffer containing 3 mM glucose at 37°C. After two washes in 3 mM
glucose modified KRB solution, the islets were incubated for consecutive 30 min incubations in 200 III of 3
and 20 mM glucose modified KRB solution. The supernatant was removed carefully for the measurement
of released insulin. To determine islet insulin content, islets were sonicated in 150 III 10mM Tris HCI,
ImM EDTA, Img/ml RIA grade BSA, pH 7.0 for 30 seconds. Fifty III ofthe solution was used to extract
islet insulin with 100 III acid ethanol at 4 °c overnight. The remainder of the sonicate was digested with an
equal volume of200 Ilg/ml proteinase K in 100 mM Tris HCl, pH 8.5, 5 mM EDTA, 0.2 % SDS at 55°C
for 2 hours and used for islet DNA quantification with picogreen kit from Molecular Probes (Eugene, OR).
Insulin was measured with the coated tube RIA kit from Diagnostic Products (Los Angeles, CA) and rat
insulin standards.

In vivo glucose tolerance test. Prior to the test, sex- and age-matched mice were fasted overnight

(about 16 hours). On the second day, mice were injected i.p. with a sterile 10% glucose solution at a dose
of 1 glkg body weight. Tail blood glucose of each mouse was measured by a glucometer (OneTouch Ultra,
Life Scan) at the times 0,5, 15,30,60, 120 min after glucose administration.
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Data analysis. Data are presented as the mean ± standard error. Statistical analysis was performed by

one-way or two-way ANOYA and Dunnet's post hoc (2-tailed) test. Computations were carried using
statistical programs from SPSS (version 10.0) and Sigmastat (version 2.03).
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Results
Transgenic mice with elevated MT expression in pancreatic beta cells.
Two independent MT transgenic lines, designated HMT-l and HMT-2, were produced in this study.
The expression level of MT in pancreatic beta cells was assessed by measuring Cd 109 binding in isolated
pancreatic islets. This assay is based on the fact that MT binds cadmium with very high affinity (Bartsch et
al. 1990). As shown in Figure 2-2, islets of lines HMT-l and HMT-2 contained 30 fold and 4 fold higher

levels of MT, respectively, than islets of FVB. This elevated expression of MT was confirmed by
immunohistochemical staining of pancreas section from line HMT -1 with MT specific antibodies (Upper
panels, Figure 2-3). HMT-l islet had enormous MT staining compared to FVB control islet whose MT
expression was barely detectable.

This figure also demonstrates that MT is specifically expressed in

pancreatic islets in that the MT expression was almost undetectable in the nearby acinar tissues of pancreas.
Similar results were obtained with line HMT-2 (data not shown).

Since several trans genes have produced unintended beta cell dysfunction (Epstein et al. 1989; Lo et
al. 1988; Wogensen et al. 1994; Wogensen et at. 1994), we also characterized HMT-l and HMT-2 islets

with respect to pancreatic islet morphology and insulin staining, isolated islet insulin content, DNA content
and glucose stimulated insulin secretion. The result showed that the insulin staining and islet morphology
appeared normal in MT transgenic islets (Lower panels, Figure 2-3). Both HMT-l and HMT-2 transgenic
islets contained similar content of islet insulin and DNA, and responded to glucose by secreting insulin to
the same extent as control FVB islets (Table 2-1). An intraperitoneal glucose tolerance test (Figure 2-4)
was performed in both transgenic lines and control FVB mice. The MT transgene, either at high or low
levels of expression, did not alter the response of whole animals to in vivo glucose challenge. These results
demonstrated that MT overexpression was not harmful to the beta cell.

Transgenic mice with beta cell specific overexpression of MnSOD and/or Catalase.
In total, five lines of MnSOD transgenic mice, designated MnSODJ, MnSOD z, MnSOD 3 , MnSOD 4 ,
MnSOD 5 , were generated in this study. Three of them had elevated SOD activity in isolated pancreatic
islets as measured by inhibition of the autooxidation of pyrogallol
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(Figure 2-5). The line MnSOD 3

contained the highest SOD activity, about 9 fold higher than FYB control. Immunohistochemical staining
with an anti-human SOD antibody verified this increased SOD activity in the pancreatic islets (Figure 2-6).
Seven lines of catalase transgenic mice were produced in our laboratory. Enzymatic activity assay,
performed by Dr. Bo Xu, revealed that all lines of catalase transgenic mice had increased levels of catalase
expression. Line 25 had the highest catalase activity (Figure 2-7).

Since MnSOD and catalase work successively to scavenge superoxide radical and HzO z, the
combination of MnSOD and catalase might provide more powerful protection in pancreatic beta cells.
Therefore in this study the line MnSOD 3 and line 25 of the catalase transgenic mice, which had the highest
level of enzyme activities, were selected for cross-breeding. Four types of offspring, nontransgenic,
MnSOD, catalase, and MnSOD plus catalase transgenic mice were produced from this breeding.
Theoretically each of them occupies 25% of the litters. The presence of transgenes in those litters was
determined by routine peR technique as shown in Figure 2-8.

Similar to the analysis performed in MT transgenic mice, the evaluation study of beta cell function
and morphology was also carried out in catalase and MnSOD transgenic mice. The insulin staining and
islet morphology appeared normal in both catalase and MnSOD transgenic islets (Figure 2-9). Either
trans gene alone or combination of MnSOD and catalase trans genes did not change the normal insulin
secretion function in isolated islets (Figure 2-10). The islet insulin content and DNA content were also
similar among transgenic and control FYB islets (Data not shown). In vivo transgenic animals with beta
cell expression of either transgene (catalase or MnSOD) or both behaved similarly to FYB control mice
after glucose administration

(Figure 2-11). These data suggested that overexpression of MnSOD or

catalase or both did not impair normal pancreatic beta cell function and structure.
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Discussion
In this part of study, we produced lines of transgenic mice with beta cell specific expression of
antioxidant proteins MT, catalase, MnSOD and MnSOD plus Catalase. Both antioxidant protein activity
assay and immunohistochemistry revealed that the antioxidant proteins were expressed and localized in
pancreatic islets. Overexpression of those antioxidants was not harmful to beta cells since the insulin
content, DNA content and insulin secretion function of transgenic islets, as well as glucose tolerance
response in transgenic mice were not different from control FVB islets or mice.

We were able to produce several transgenic lines for each of our transgenes. Part of this success was
due to use of the FVB mouse strain. This inbred strain that has been widely used to produce transgenic
mice. At each step of transgenic technique procedure, FVB mouse have been shown to have the highest
efficiency compared to other strains such as Swiss Webster (SW) outbred and C57BLl6 inbred mice. FVB
mice are easy to superovulate and its embryo is relative large, thereby relatively easy for manipulation of
trans gene microinjection. The fertilized eggs ofFVB mouse survive much longer than those from C57BL/7
inbred or other strains. FVB mouse are also productive and easy to breed (Taketo et at. 1991; Auerbach et
at. 2003).

Our transgenic mice were created by microinjection technique. This technique allows the foreign
transgene sequence to integrate into the host genome by a DNA recombination known to be largely random
(Copeland et at. 2001). Multiple insertion sites and incorrect insertion orientation may both occur.
Therefore the expression levels of the same transgene in different transgenic lines could be highly variable.
In this study each line had a very different expression level of antioxidant protein. A few of them even
contain no increase in activity compared to the control mice although they were all shown positive for the
transgene by tail DNA PCR. The low level of expression was probably due to a bad insertion site. Due to
variable expression in different lines studies on multiple lines of transgenic mice are usually required
(Pujol-Borrell & Bottazzo 1988).
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However, from another point of view, the variation of transgene expression makes it possible to test
the effect of protein dosage (Black, Jr. et al. 2002). Different levels of gene expression may trigger cellular
process at different degrees and thus lead to different levels of biological function or phenotype. Such a
study assures a more complete identification of the potential of the transgene. As seen in our MT transgenic
mice, the line of HMT -1 has a higher expression of MT than the line of HMT-2. We found that the higher
level of expression of MT produced more protection (shown in Figure 3-13). In this project three types of
antioxidant transgenes with different ROS scavenging spectrum were selected. For each transgene at least
two lines of transgenic mice with different levels of antioxidant expression were maintained. Consistent
results with two different transgenic lines eliminates the possibility that insertional mutagenesis could
cause observed phenotypes. Therefore the conclusions drawn from these mice should be specific and
reliable.

All of our trans genes were regulated by the rat or human insulin promoters. The insulin promoter
drives the antioxidant gene expression specifically in the beta cells. We have confirmed this specificity
with immunohistochemical staining in pancreatic sections. However, the insulin promoter, especially the
rat insulin promoter may also drive the transgene to express in other types of tissues (Sarvetnick et al.
1988). Apart from the expression in pancreatic islets, our catalase transgene has been shown to be also
expressed in liver and kidney, at a very low levels (Xu et al. 1999). Such ectopic expression might be
critical to interpret the resultant data under certain situations, for example in the NOD mouse. Since the
beta cell destruction in NOD mouse is mediated by an immune reaction, the expression of antioxidant
trans gene in immune system could alter the overall effect in the transgenic mice. Unfortunately, we have
not carried out studies to examine the expression pattern of MT and MnSOD transgenes in the immune
system. This needs to be completed in the near future.

We analyzed the isolated islet function and structure as well as the glucose tolerance response in the
transgenic mice. The results from these studies imply that our transgenic mice or beta cells are normal
compared to FVB controls. These are important analyses because trans gene expression may produce
unintended beta cell dysfunction and cell death (Epstein et al. 1989; Lo et al. 1988; Wogensen et al. 1994).
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Several reasons may explain this unexpected effect. DNA recombination between transgene and host
genome is completely random; thereby some host genes, important for beta cell function and survival,
might be disrupted. The transgene itself is highly expressed which is not physiological. The overproduction
of transgenic protein could be a stressful burden to beta cells (Contreras et

at. 2003). For undetermined

reasons some transgenes have been found to modify normal cellular physiological signal pathways and
promote beta cell death (Epstein et at. 1989). However, in this research we were lucky enough to establish
lines of antioxidant transgenic mice without damaging normal beta cell function and morphology. This
allowed us to further investigate their potential roles in diabetes onset and development.
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Figure 2-1. Scheme of antioxidant transgene construct. The antioxidant transgene was regulated by a rat
or human insulin promoter, which allowed a specific expression in pancreatic beta cells. Following the
insulin promoter was the gene or cDNA of interest containing coding sequences for rat catalase, human
MnSOD or human MT-U gene. An SV-40 enhancer sequence and poly A sequence were placed in the
downstream portion of the antioxidant gene for efficient expression and processing in the transgenic mice.
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Figure 2-2. Elevated MT expression in isolated islets of HMT-l and HMT-2 transgenic mice. The
level of MT was indicated by cadmium binding activity in islet extracts as described in the methods. Four
or more assays using at least 100 islets were performed for each point. An asterisk indicates different from
FVB by p<O. 01 by AN OVA and Dunnet' s post hoc test. Vertical bars indicate the standard error.
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Figure 2-3. Increased MT immunostain in g and normal insulin staining in HMT-l islets. Islets in A

(FYB) and B (HMT- I) were stained with a monoclonal anti-horse MT primary antibody.

Islets in C

(FYB) and 0 (HMT-I) we re stained with a rabbit anti-guinea pig insu lin primary antibody. Magnification
x200.
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TABLE 2-1. Characteristics of FVB control and MT transgenic islets.
Glucose induced insulin
DNA (ng/islet)

Insulin (/-lU/ng DNA)
secretion (20mM/3mM glucose)

FVB

11.48±0.61

190.9 ± 7.28

8.14 ± 1.22

HMT-1

12.20 ± 1.84

172.5 ± 19.9

8.10 ± 2.07

HMT-2

12.85 ± 1.57

161.9±11.6

8.48 ± 1.14

Data are the means

± SE from at least 9 assays.

among groups.
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No significant differences were found

300

-o-FVB
-e- ·HMT1
- • - HMT2

250

--=-

200

0

150

"C

C)

E
Q)

1/1
to)

:::I
C)

"C

0

100

.2

m
50
0

--,

0

20

40

60

80

100

120

minutes post glucose injection

Figure 2-4. Glucose tolerance test in MT transgenic and control FVB mice. Mice were fasted for 16
hrs and then received an intraperitoneal injection of 1 gram glucose/kg bodyweight. Blood glucose levels
were measured with a Lifescan glucometer at the indicated time after injection. Each group contained at
least seven animals. Vertical bars indicate the standard error of the mean. No significant difference was
present among either line of transgenic mice and control mice by two-way ANOVA.
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Figure 2-5. SOD activity in isolated islets from five lines of MnSOD transgenic mice and control FVB
mice. SOD activity was measured by inhibition of the autooxidation of pyrogallol as described in the

Materials and Methods. At least six assays from three islet isolations were performed for each group. Three
out of five lines of transgenic mice have elevated pancreatic islet SOD activity. The
from FVB (p<O.OI by one way ANOVA). Vertical bars indicate the standard error.
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* indicates different

Figure 2-6. Elevated SOD immunostaining in MnSOD transgenic islets compared to FVB control
islets. (A) FVB, (B) MnSO D5. Pancreas sections were stained with a sheep anti -h uma n MnSO D primary
antibody. Magnification x400.
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Figure 2-7. Increased catalase activity in isolated islets of catalase transgenic mice.

Activity is

expressed as equivalent milliunits of purified bovine catalase per islet. Three or more assays were
performed on at least 100 islets from each transgenic line. Vertical bars indicate the standard error. Graph
was adapted from the work of Dr. Bo Xu, et at. (Xu et at. 1999).
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Figure 2-8. peR identification of MnSOD and catalase transgenes in offspring from cross-breeding
of MnSOD (line 3) a nd catalase (line 25) transgenic mice. This is a typical gel showing PCR products
of MnSOD and cata lase transgenes. Each lane represe nts an individual mouse. Lane I to Lane 9 are DNA
samples from the offspring;

(F) negative control of FVB mOllse DNA ; (S) positive control for MnSOD

transgene. (C) positive control of catalase transgene. MnSOD transgene gives a product abollt 800 bp;
Catalase transgene gives a product about 850 bp; the band with a size abollt 490 bp is a product of heme
oxygenase gene which is expressed in every type of our mice. Mice I and 9 ca rri ed only MnSOD
tran sgene, mice 2 and 8 carried catalase transgene, and on ly mice 4,5 and 7 carried both transgenes,

whereas mice 3 and 6 did not contain any transgene.
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Figure 2-9. Normal insulin immunostaining and islet morphology in catalase and MnSOD transgenic
islets. A and Care FVB contro l islets. B shows islets from catalase transgenic mice. 0 shows MnSOO
transgenic is lets. Pancreas sections were stained with a rabbit an ti-guinea pig insulin primary ant ibody, and

colored by flu orescein (A and B) or AEC (C and 0). Magnification x200.
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Figure 2-10. Basal (3mM glucose) and 20 mM glucose stimulated insulin secretion in MnSOD,
catalase (Cat), MnSOD plus catalase (MnSOD+Cat) transgenic islets and control FVB islets. Insulin
secretion assay was performed on 6 to 10 islets in a 96-well plate as described in Materials and Methods.
Four independent measurements were carried out per group. Vertical bars indicate the standard error. No
statistical difference was found among four groups by two-way ANOV A, indicating that transgenic islets
and FVB control islets had similar insulin secretion responses to glucose stimulation.
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Figure 2-11.

Glucose tolerance test in MnSOD, catalase

(CAT), MnSOD plus catalase

(MnSOD+Cat) transgenic and control FVB mice. Mice were fasted for 16 hrs and then received an
intraperitoneal injection of 1 gram glucose/kg bodyweight. Blood glucose levels were measured with a
Lifescan glucometer at the indicated time points after injection, Each group contained at least six animals,
Vertical bars indicate the standard error, Neither MnSOD/catalase transgene alone nor combination of
these two transgenes changed glucose tolerance responses (P>O,05 by two-way ANOVA),
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CHAPTER III
THE PROTECTIVE EFFECT OF ANTIOXIDANT TRANSGENES AGAINST ROS INDUCED
PANCREATIC BETA CELL DESTRUCTION AND STREPTOZOTOCIN INDUCED DIABETES

Introduction

In both Type 1 and Type 2 diabetes excessive ROS are thought to be produced in pancreatic beta cells
by multiple processes regulated by a variety of factors (Cnop et at. 2001; Ihara et at. 1999; Kessler et al.
1996; Rabinovitch et al. 1992; Rabinovitch 1998). Compared to other cell types, pancreatic beta cells are
exceptionally susceptible to ROS induced damage. A striking example for this vulnerability of beta cells is
the severe damage done by streptozotocin

(STZ). This natural toxin has several destructive actions,

including DNA methylation (Murata et at. 1999), protein modification (Liu et al. 2000b), and ROS
generation (Ohkuwa et al. 1995). STZ enters the cytoplasm via GLUT2 (Schnedl et at. 1994), which is the
B-cell's glucose transporter. The presence of this transporter may account for part of the specific
vulnerability of the B-cell. However, GLUT2 is also present in the liver and kidney, tissues that are
relatively resistant to STZ damage. The much greater sensitivity of the B-cell is probably due to its very low
level of antioxidant enzyme expression and activity, particularly hydrogen peroxide-inactivating enzymes
catalase and glutathione peroxidase, which are only 2% as active as they are in liver (Grankvist et al.
1981 b; Lenzen et at. 1996; Tiedge et al. 1997). In addition, the adaptive properties of antioxidant enzyme
gene expression are very limited in insulin-producing cells (Tiedge et al. 1997). Therefore, increasing
pancreatic beta cell antioxidant expression is an attractive strategy to strengthen beta cell resistance to
oxidative damage, thereby protecting from diabetic destruction.

A variety of studies have been carried out in vitro using insulin secreting cell lines to test whether
elevated antioxidant enzymes could confer protection against ROS damage. Tiedge and his colleagues
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(Lortz et al. 2000; Tiedge et al. 1998; Tiedge et al. 1999) bioengineered RINm5F cells with high
expression of glutathione peroxidase, catalase and CU/Zn SOD. Elevated expression of those antioxidants
greatly improved cellular resistance of RINm5F cells to oxygen free radicals and NO insults. Moreover
those cells are very resistant to cytokine-mediated toxicity. This is also true in other lines of insulin
secreting cells. In INS-l cells the resistance to interleukin-l ~ is remarkably elevated due to a stable
overexpression of MnSOD (Hohmeier et al. 1998), and the resistance to oxidative stress is greatly
enhanced through an adenoviral-mediated glutathione peroxidase overexpression (Moriscot et al. 2003). In
some other studies increased antioxidant expression in isolated human, rat and porcine islets (Bottino et al.
2002; Benhamou et al. 1998) by adenoviral gene transfer also provided protection from oxidative damage.
However, extensive investigations have not been carried out in vivo. Therefore in this project we developed
beta cell protected animals instead of beta cell protected cell lines with beta cell specific overexpression of
three types of antioxidants: MT, catalase and MnSOD. In this part of the study these animals were
evaluated for their resistance to ROS damage and STZ induced diabetes.
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Materials and Methods
Chemicals: 5-

(6)-chloromethyl-2', 7' -dichlorodihydrofluorescein diacetate

(CM-H 2DCFDA),

picogreen was purchased from Molecular Probes (Eugene, OR). Alarma Blue was bought from Biosource
International (Camarillo, CA). H20 2, hypoxanthine, xanthine oxidase, 3-morpholinosydnonimine (SIN-I),
S-nitro-N-acetyl-penicillamine (SNAP), and streptozotocin were bought from Sigma (St. Louis, MO).
Polyclonal anti-rabbit nitrotyrosine antibody was supplied by Upstate biotechnology (Charlottesville, VA).
Other non-indicated chemicals were standard reagents from Sigma, Fisher Scientific, or Amersham
Biosciences.

Dispersion of islets into single cells. Overnight cultured islets were dispersed by trypsin digestion
with a modified procedure as described by Appels et al. (Appels et al. 1989). Briefly, 100 to 200 islets were
hand picked into 1.5ml microtube and rinsed with HBSS solution twice. After removal of most medium,
500 I.d digestion buffer (HBSS solution, Ca2+ and Mg 2+-free, no phenol red but containing 0.0075%
trypsin, 3mM EGTA, 2mg/ml Glucose and 20mg/ml RIA graded BSA) was added to the islet pellets.
Digestion was carried at 37°C for 10 minutes. Islets were then mechanically dispersed into single cells by
50 to 80 times of repeated pipetting with a gel loading tip (0.37JlM diameter). After two washes of fresh
culture medium (no phenol red), single islet cells were resuspended in 500 JlI culture medium without
phenol red for next uses.

Measurement of ROS production in dispersed islet cells. A cell membrane-permeable and oxidant
sensitive fluorescent dye 5-

(6)-chloromethyl-2', 7' -dichlorodihydrofluorescein diacetate

(CM-

H2DCFDA) was utilized to indirectly measure ROS (Li et al. 2003). The dispersed islet cells were loaded
with 10 JlM CM-H2DCFDA for 30 min followed by three washes of fresh islet culture medium without
phenol red. The cells were re-suspended in culture medium without phenol red and cell numbers were
counted. These dispersed islet cells loaded with CM-H2DCFDA were distributed into a 96-well plate at
concentration of 40,000 cells per well in 200 Jll islet culture medium without phenol red. The exogenous
sources of ROS: H20 2, SIN-lor hypoxanthine/xanthine oxidase, were quickly added to the wells. Right
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after addition of ROS, the increase of fluorescence intensity in each well was measured continuously for 4
to 6 hours at room temperature on a fluorescent microplate reader (Tecan, Durham, NC) at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm. The data were expressed as increased
fluorescent intensity per well.

Cell viability assay by Alamar Blue. The Alamar Blue assay, which incorporates a redox indicator
that changes color and fluorescence in response to cell metabolic activity, is a commonly used method to
assess cell viability and/or proliferation of mammalian cells

(Gonzalez & Tarloff 2001) and micro-

organisms (Byth et al. 2001). In our studies, 15 ovemight-cultured FVB control islets or transgenic islets
were hand picked into 200 /-ll fresh culture medium (no phenol red) containing 1:20 diluted Alamar Blue in
a 96-well plate. Islets were cultured for 4 hr and the Alamar Blue fluorescence was measured on a
fluorescent microplate reader (Tecan, Durham, NC) at the excitation wavelength of 535 nm and the
emission wavelength of 595 nm. This measurement provided an absorbance value indicating the
pretreatment metabolic activity and was used to normalize the post-treatment metabolic activity. After
three washes with fresh culture medium, islets were cultured in 200 /-ll culture medium containing various
agents, including HzO z and STZ, at various concentrations for varying time. In the end of treatment, fifty fll
culture medium was replaced with 50 fll fresh culture medium containing 1:5 diluted Alamar Blue, for a
final dilution of 1:20. The color was developed for another 4 hr and the fluorescence was measured again.
A fluorescent value from the "blank well", which contained no islets but exactly followed the above
procedure with highest level of ROS treatment, was deducted from all other fluorescent values. Islet cell
viability was calculated as the ratio of fluorescence after treatment to the fluorescence before treatment.
The untreated islet cell viability was arbitrarily set as 100%.

Nitric oxide in vitro studies. Isolated FVB and HMT-l islets were exposed to different
concentrations of a nitric oxide donor, SNAP for 24 hours. Apoptotic and necrotic DNA were detected with
an anti-histone biotin/anti-DNA POD ELISA

plus

kit (Roche, Indianapolis, IN) based on the manufacturer's

instructions. Briefly, 40 to 50 islets were cultured for 24hrs in 500 fll fresh culture medium in a 1.5ml
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microtube with or without SNAP treatment. After treatment the microtube was centrifuged at 200x g for 10
minutes at 4°C. The supernatant was removed as the necrosis DNA sample. The pellet was lysed with 100
f.lllysis buffer for 30 minutes at room temperature. The microtube was centrifuged again at 200x g for 10
minutes at 4°C. The supernatant was removed as apoptotic DNA sample. To quantify the necrotic and
apoptotic DNA, both DNA samples were added to the streptavidin-coated microplate contained in this antihistone biotin/anti-DNA POD ELISA

plus

kit. All values were normalized to islet total DNA measured by

picogreen DNA quantification (Molecular Probes, Eugene, OR).

In vitro STZ treatment. Overnight incubated islets were handpicked into 2 ml (for islet DNA
damage and NAD+ measurements in 24-well tissue culture plate) or 200 III (for islet cell viability and
insulin content assays in 96-well tissue culture plate) islet culture medium. Within 1 min before use, STZ
was dissolved in 4°C O.IM sodium citrate (pH 4.5). Ten microliters of this solution were added to the islets
to obtain the required STZ concentrations. Islets were incubated at 37°C in humidified air and 5% CO 2 for a
period of time as indicated in the Results. After treatment, the islets were retrieved for assessment of cell
viability assayed by Alamar Blue, preserved islet insulin content measured by an anti-insulin antibody
coated tube RIA kit (Diagnostic Products, Los Angeles, CA) in MnSOD and catalase transgenic islets, and
measurement of DNA fragmentation and NAD+ level in HMT-l transgenic islets.

Analysis of STZ fragmentation of islet DNA. STZ-treated and untreated islets were washed with
HBSS and then digested with 50 f.ll 200 f.lglml proteinase K in 100 mmol/l Tris-HCl, pH 8.5, 5 mmol/l
EDTA, and 0.2% SDS at 55°C for 2 h. The islet DNA was then purified with the Prep-A-Gene DNA
purification kit from Bio-Rad. After quantification of DNA concentration using the picogreen kit from
Molecular Probes, equal amounts of sample DNA were loaded on a 0.3% SeaKem Gold agarose (FMC
Bioproducts) gel. The gel was run at 21 Volts in 0.04 mol/l Tris-acetate and 0.001 molll EDTA buffer for 6
h and stained with 0.5 f.lg/ml ethidium bromide.

Measurement of STZ-induced depletion of NAD+. STZ-treated and untreated islets were washed in
HBSS and disrupted in 250 f.ll precooled 0.1 mol/l bicine (pH 7.8) by freeze/thaw, followed by sonication.
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The sample was centrifuged at 16,000x g for 10 min, and 100 /11 of the supernatant was applied for NAD+
determination by an alcohol dehydrogenase cycling method

(Shah et at. 1995). Briefly, 100 /11 of

supernatant was reacted with 100 /11 freshly prepared reagent mix (to obtain final concentration of 0.1 molll
bicine [pH 7.8], 0.5 mol/l ethanol, 4.17 mmolll EDTA-Na4, 0.83 mg/ml BSA, 0.42 mmol/l 3-[4,5dimethylthiazol-2-yl]-diphenlyltetrazolium bromide [MTT], 1.66 mmol/l phenazine ethosulfate, and 1.25
units/ml alcohol dehydrogenase). The reaction was carried out on a 96-well microplate. Color was
developed in the dark at room temperature for 45 min, and the absorbance was read at 560 nm. Sample
NAD+ concentrations were calculated from an NAD+ standard curve. Values were expressed per microgram
of islet protein in the sonicate, as measured with the Pierce BCA kit.

In vivo STZ treatment. For MT transgene study, a total of 12 HMT-2 mice, 16 HMT-l mice, and 26

control FVB mice, and for MnSOD/catalase trangene study, a total of 16 control FVB mice, 16 catalase
mice, 15 MnSOD mice, and 16 MnSOD plus catalase mice, received a single intraperitoneal injection of
freshly dissolved STZ in 0.1 mol/l sodium citrate (pH 4.5) at a dose of 220 mglkg body weight. Mice were
sex-matched at the age between 10 and 17 weeks. The tail blood glucose levels were monitored daily up for
eight days after STZ treatment by a glucometer (OneTouch Ultra, Life Scan, Milpitas, CA). Some mice
were sacrificed 30 or 48 hours after STZ administration. The pancreata were removed and sectioned for
immunohistochemical staining of nitrotyrosine, or the pancreatic islets were isolated for electron
microscopy.

Immunohistochemistry for nitrotyrosine. STZ untreated or treated mouse pancreata were fixed in

10% formaldehyde in 0.1 mollL phosphate buffer (pH 7.2), dehydrated in an ascending graded series of
ethanol, and subsequently infiltrated with paraffin. Serial section were cut at 5 /1m, mounted on polylysinecoated slides, and then deparaffinized in xylenes and a descending graded series of ethanol. To stain
nitrotyrosine, slides were treated with target retrieval solution

(Dako corporation, Carpinteria, CA),

followed by M.O.M mouse Ig blocking reagent (Vector Laboratories, Burlingame, CA). Polyclonal antirabbit nitrotyrosine antibody (Upstate biotechnology, Charlottesville, VA) was added to the slides at a
dilution oh 1:800 and incubated overnight at 4°C. After 3 washes in phosphate-buffered saline, slides were
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incubated with biotinylated anti-mouse IgG reagent, followed by ABC reagent and developed with DAB as
chromagen. Slides without primary antibody treatment were used as negative control. The positive
nitrotyrosine signal was obtained in the slides that were pre-treated with commercial peroxynitrite
(Sigma).

Electron microscopy. Isolated pancreatic islets were centrifuged to a soft pellet and prepared for

transmission electron microscopy by techniques previously described

(Carlson et al. 1997). In brief,

fixation was carried out for 2-4 h in cold (4°C) Kamovsky's (Kamovsky 1965) fixative (pH 7.4). The
pellets were then rinsed in 0.2 molll sodium cacodylate buffer, postfixed in 1% Os04 at 4°C (90 min), and
rinsed with distilled water. Dehydration was carried out in graded ethanols and propylene oxide. Pellets
were embedded in EponJAraldite and cured for 48 h at 55°C. Epoxy blocks were thin-sectioned (silver-gray
interference color) with a Diatome diamond knife. Sections were mounted on 200-flm mesh naked copper
grids and stained with lead citrate and uranyl acetate (4% in absolute ethanol). Sections were observed and
photographed in a Hitachi 7500 transmission electron microscope.

Data analysis. Data are presented as the mean ± standard error. Statistical analysis was performed by

one-way or two-way ANOY A and Dunnet's post hoc (2-tailed) test. Computations were accomplished
using statistical programs from SPSS (version 10.0) and Sigmastat (version 2.03).
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Results
Enhanced ROS scavenging capacity in transgenic beta cells. To detennine whether the antioxidant
trans genes enhance pancreatic beta cell ROS scavenging ability, the dispersed single islet cells from control
FVB mice and transgenic mice were exposed to different concentrations of superoxide radical produced by
hypoxanthine and xanthine oxidase (Figure 3-1), peroxynitrite radical generated from SIN-l (Figure 3-2)
and H20 2 (Figure 3-3). Beta cell ROS production was measured with CM-H 2DCFDA that had been
preloaded into the islet cells prior to ROS addition. ROS oxidized CM-H2DCFDA, causes an increase of
fluorescence intensity. Thus cellular fluorescence provides an indication of intracellular ROS levels. Our
data showed that the catalase trans gene made pancreatic beta cells more effective in scavenging all three
ROS sources. MnSOD transgenic islet cells disposed of superoxide radical and peroxynitrite more
efficiently than control FVB islet cells. However, the MnSOD transgene promoted H20 2 induced CMH2DCFDA oxidation, indicating the level of beta cell ROS in the presence H20 2 of was increased rather
than reduced by MnSOD expression. Actually, even under basal conditions, ROS levels in MnSOD
transgenic islet cells already tended to be higher than in control FVB islet cells (Figure 3-1 A). The
combination of MnSOD and catalase trangenes enabled beta cells to more effectively scavenge all three
ROS sources. The islet cells containing both transgenes were especially potent in their ability to detoxify
SIN-l generated peroxynitrite radical compared to the islet cells containing either transgene alone (Figure
3-2). This suggests an additive or synergistic action of MnSOD and catalase in scavenging of peroxynitrite
radical.

Since the MnSOD transgene enhanced beta cell ROS production after H20 2 exposure, it should also
be true that MnSOD transgenic islets would have a higher sensitivity to H20 2 toxicity. Therefore we
perfonned a cell viability assay by measuring islet metabolism with Alamar Blue. As shown in Figure 3-4,
catalase alone or MnSOD plus catalase significantly decreased H20 2 induced islet cell death. However the
MnSOD transgene by itself sensitized islet cells to H 20 2 toxicity. From the above data we demonstrated
that overexpression of MnSOD and/or catalase enabled pancreatic beta cells to discard most forms of ROS
more potently. MnSOD and catalase worked together to dispose of peroxynitrite, but MnSOD itself
enhanced H20 2 toxicity to beta cells.
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MT has been recognized as an ROS scavenger with high competence in scavenging of nitric oxide
radicals (Sato & Bremner 1993), superoxide radicals (Lazo et al. 1998), hydroxyl radicals (Kumari et at.
1998), and peroxynitrite (Cai et at. 2000). In this study a similar CM-H2DCFDA measurement of ROS
was carried out in our laboratory by Xiaoyan Li. The dispersed HMT -1 transgenic and control FVB islet
cells were exposed to three ROS sources: superoxide radial from the reaction of hypoxanthine and xanthine
oxidase, SIN-l derived peroxynitrite and H20 2. As shown in Figure 3-5, beta cell ROS production was
dramatically reduced by the MT transgene following exposure to all three ROS sources. Islets were also
exposed to nitric oxide by incubation with SNAP, a nitric oxide donor. SNAP did not increase CMH2 DCFDA fluorescence in our assay probably because CM-H2DCFDA is not sensitive to nitric oxide
radical; consequently we assessed MT induced resistance to nitric oxide by observing islet morphological
changes and quantitating islet cell death as measured by DNA cleavage. As shown in Figure 3-6, MT
transgenic islets were more resistant to SNAP induced morphological damage and cell death than control
FVB islets. These data demonstrate that the beta cells containing MT trans gene are capable of scavenging
all or most forms ofROS.

Protective effect of MnSOD and catalase transgenes against STZ induced beta cell toxicity and
diabetes. Since MnSOD and/or catalase greatly enhance pancreatic beta cell ROS scavenging capacities,
further studies were employed to test whether MnSOD and catalase provided protection against STZ
induced beta cell death and diabetes. STZ is a commonly used diabeteogenic agent which produces ROS
and specifically destroys pancreatic beta cells (Flodstrom et al. 1999; Ohkuwa et at. 1995). In our study the
islet cell viability and preserved islet insulin content were measured in transgenic islets (MnSOD, catalase,
or MnSOD plus catalase) and control FVB islets after exposure to STZ for two days. As shown in Figure 37, either MnSOD or catalase transgene tended to reduce STZ induced islet cell death and insulin content
loss a little bit. But this protective effect was remarkably amplified when MnSOD and catalase were
present together in the beta cell.
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decrease in the strength of the band running above 48 kb was taken as the primary indicator of STZ-induced
DNA damage. MT clearly protected this high-molecular weight band, particularly at the lower doses of
STZ. In control islets, the high-molecular weight DNA declined at concentrations between 0.25 and 0.5
mM STZ. In islets overexpressing MT, this degree of degradation did not occur until a concentration of 1.0
mM STZ was reached. DNA protection by MT was found in seven consecutive experiments. These results
demonstrated that MT increases the threshold for DNA damage. However, this protection was breached by
doubling the dose of STZ. In no instance did we see a DNA ladder characteristic of apoptosis. DNA
cleavage by STZ occurs at largely random sites (LeDoux e/ al. 1986), due to chemical attack rather than
regularly spaced sites produced by enzymatic cleavage, as seen in apoptosis.

STZ-induced depletion of cellular NAD+ is thought to be a consequence of DNA damage (Masutani e/
al. 1999). Therefore, we anticipated that MT would protect cellular NAD+ content. This was tested in islets

exposed to STZ under the same conditions used for DNA damage analysis. As shown in Figure 3-12, MT
overexpression right-shifted the dose response curve for depletion ofNAD+. Because it is the lack ofNAD+
that ultimately causes the downfall of the B-cell, this result indicates that MT overexpression can prevent Bcell death and diabetes.

For In vivo analysis, both lines of MT transgenic and control mice received a single injection of STZ.
Blood glucose levels were monitored for the next 6 days after STZ administration. The data shown in
Figure 3-13 indicated that the onset of diabetes was remarkably delayed by the MT transgene, particularly
in HMT-1 mice. In control animals, blood glucose values >400 mg/dl usually occurred 2 days after the
administration of STZ. A similar degree of diabetes required 3 days in HMT-2 mice and did not occur
during the 6-day observation period in HMT -1 mice.

The damage of STZ resulted in morphological changes to islet cells. MT overexpression prevented
this destruction. After two days of STZ administration, we isolated islets and made morphological
observations in HMT-1 and FVB islets by electron microscopy (Figure 3-14). We found untreated HMT-1
islets appeared normal and were indistinguishable from untreated FVB islets (Figure 3-14 A and B). After
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STZ treatment, islet preparations from FVB mice showed markedly different morphological features
(Figure 3-14 C). In these preparations, many cells, putatively identified as beta cells, exhibited several
features of necrosis, including vacuolization, moth-eaten mitochondria, dilated cisternae of rough
endoplasmic reticulum, and electron-lucent cytoplasm. Beta cells in these preparations showed fewer
granules than their untreated counterparts, and many were morphologically disorganized or necrotic. In
contrast, islets isolated from STZ-treated HMT-1 transgenic mice showed no evidence of necrosis, and
though some beta cells were moderately degranulated, vacuolization and biomembrane discontinuities were
not seen (Figure 3-14 D).
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Discussion

In this part of study we explored whether the antioxidant transgenes MnSOD, catalase, MnSOD plus
catalase, and MT could effectively scavenge ROS and could protect against ROS induced pancreatic beta
cell destruction and STZ-induced diabetes.

By measuring CM-H2DCFDA oxidation, we verified that

overexpression of these antioxidants greatly enhanced beta cell ROS scavenging abilities. Cell viability
assays, DNA fragmentation assays and insulin content measurements confirmed the protective effect of
these antioxidants. The pancreatic beta cells containing these antioxidants proteins, with the exception of
MnSOD, were more resistant to the toxicity of H 20 2, nitric oxide and STZ compared with FVB control
cells. MnSOD actually increased measured ROS levels and sensitized toxicity to beta cells when exposed
to H20 2. The protective effect against STZ-induced diabetes was also investigated in these antioxidant
transgenic mice. The result showed that all of these antioxidant transgenes tended to delay and reduce STZ
induced diabetes. The MT transgene significantly suppressed STZ-induced beta cell morphological
damage. MnSOD and catalase trans genes worked synergistically to prevent ROS damage as the
combination of these two trans genes not only made beta cells more efficient in scavenging peroxynitrite
radical and peroxynitrite derived protein nitrotyrosine production, but also made mice more resistant to
STZ induced diabetes than either transgene alone.

This synergistic action of MnSOD and catalase comes from their enzymatic actions. The ROS
scavenging reactions of these two antioxidants are sequentially linked. MnSOD is located in the
mitochondrial which is the main site for production of superoxide radical. MnSOD converts superoxide to
H20 2 and oxygen. H20 2 can freely diffuse through the mitochondrial membrane into the cytoplasm and
peroxisome where catalase is located. H20 2 is then detoxified by catalase to water. These processes are
very important for beta cell survival under oxidative stress since pancreatic beta cells contain very low
levels of antioxidant protein expression and activity, particularly catalase and glutathione peroxidase
(Lenzen et al. 1996). Simple overexpression of MnSOD will increase H20 2 production with which the beta
cell is poorly equipped to deal. Therefore simultaneous overexpression of both MnSOD and catalase
renders the beta cell much more effective in dealing with ROS than either single trans gene alone. Not only
our results, but results from other studies indicated this benefit of combined antioxidants. In Drosophila

S6

Melanogaster, overexpression of both SOD and catalase significantly extended its life-time and retarded
aging related-protein oxidative damage while neither protein alone was effective (Orr & Sohal 1994). In
the beta cell line RINm5F, combined expression of Cu/Zn SOD plus catalase or CU/Zn SOD plus
glutathione peroxidase provided more protection against H20 2 , superoxide radical, and NO than single
expression of either transgene (Tiedge et al. 1998; Tiedge et al. 1999). In the same RINm5F cells, coexpression of MnSOD and catalase provided an even better protection against H20 2 than did co-expression
of Cu/Zn SOD and catalase, indicating the important role of mitochondria in ROS production (Lortz &
Tiedge 2003). In cultured rat islets, Uchigata et at.

(Uchigata et al. 1982) demonstrated that co-

administration of SOD and catalase more effectively prevented alloxan induced islet DNA breaks and proinsulin biosynthesis inhibition than did each ROS scavenger alone. All these results suggest that the best
protection of pancreatic beta cells against ROS destruction is achieved by a coordinated inactivation of
various types of ROS by a combination of antioxidant enzymes rather than any single enzyme in isolation.

Some earlier studies questioned the role of ROS in producing beta cell damage by STZ. In the study
ofUchigata et.al. (Uchigata et al. 1982) neither SOD nor catalase was found to prevent STZ induced islet
DNA breaks and inhibition of pro insulin synthesis. Also other studies reported that SOD failed to protect
against the diabetogenic action of STZ (Gold et al. 1981) Therefore, Uchigata et at. proposed that, unlike
alloxan, STZ- induced beta cell DNA damage was mediated by an alkylating activity ofSTZ itself (Murata

et al. 1999) rather than mediated by STZ generated ROS. In our studies we found that MnSOD was
protective against STZ, but the effect of MnSOD alone was quite weak. However when combined with
catalase, MnSOD was very effective. Therefore that data supports the ROS mechanism of STZ toxicity.
Our study with the MT antioxidant also clearly showed protection from STZ induced beta cell DNA
fragmentation and beta cell death, further supporting the role of ROS. In fact it has been proven that both
NO (Kroncke et al. 1995), hydroxyl radical (Gille et al. 2002), and H20 2 (Takasu et at. 1991) are
generated by STZ and they greatly contribute to beta cell DNA damage. The reason for those studies that
failed to observe the protective effect of antioxidants against STZ probably is due to the limitation of their
procedure in delivering antioxidants. With their procedure, the amount of antioxidants reaching the target
beta cells could not be as high as that achieved by our trans genes.
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Another interesting finding in this study is that MnSOD overexpression appears to increase H20 2
induced ROS production and sensitizes H20 2 toxicity to beta cells. This finding is consistent with some
other studies performed in beta cell lines where SOD either is shown to be not protective against or
sensitizing to the toxicity of some types of ROS. For example, in insulin secreting RlNm5F cells
overexpression of SOD does not alter the resistance of the cells to H20 2 but sensitized to the toxicity of
menadione and butylalloxan (Tiedge et al. 1998; Tiedge et al. 1999). This increased sensitivity due to SOD
overexpression is more widely reported in the field of cancer research (Kim et al. 2001; Li et al. 1999;
Zhong et al. 1996). In numerous transformed cancer cell lines, the overexpression of MnSOD results in an
increased ROS level under basal cell culture condition

(Li et al. 1998), and leads to reversion of

tumorigenicity in vivo (Church et al. 1993; Kim et al. 2001) and loss of the malignant phenotype in vitro
(Li et al. 1998; Zhong et al. 1996). Unfortunately, the mechanism underlying the tumor-suppressing ability
of MnSOD has not been defined. A prevailing thought is that an imbalance in the redox state of the cells
causes an inhibition of cell growth, though the precise role of excess MnSOD is not known. In theory,
scavenging of superoxide anion by MnSOD leads to an increase in H 20 2, and without a concomitant
increase in the peroxide-scavenging enzymes, this oxygen intermediate may become toxic. In the
mitochondrial microenvironment, excess H20 2 would be available to react with Fe2+, contained in multiple
Fe-S electron transport chain components, leading either to the production of hydroxyl radical via HaberWeiss reaction (Liochev 1996) or offerry or perferryl species (Hare1 & Kanner 1988).

In our studies, the H20 2 was added in the culture medium. Some ROS produced could enter the
mitochondria and form superoxide. Excess MnSOD would convert this to H20 2 which through the HaberWeiss reaction can form more potent ROS such as hydroxyl radical. Thereby the overall effect on beta
cells would be more toxic. However if catalase was also overexpressed in the beta cells, H20 2 would be
decomposed rapidly.

The protective value of MT in the B-cell was anticipated because MT is an antioxidant protein (Sato
& Bremner 1993), B-cell toxins induce it (Minami et al. 1999; Ohly & Gleichmann 1995; Ohly et al.
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2000), and MT has demonstrated efficacy against DNA damage in other cell types

(Chubatsu &

Meneghini 1993). These facts led several laboratories to examine whether increased levels of MT could
produce a more resistant B-ceU. Initial results were very promising. Ohly et al.

(Ohly & Gleichmann

1995)showed that, after STZ treatment in vitro, induction of MT with zinc pretreatment helped preserve
islet function and prevented diabetes induced by multiple low doses of STZ treatment in vivo (Ohly et al.
2000). However, zinc has actions other than MT induction (Bray & Bettger 1990; Vallee & Falchuk 1993).
A particularly relevant example of zinc actions that are independent of MT is shown in the report by
Apostolova et al. (Apostolova et al. 1997), who found that, in mice lacking functional MT 1 and II genes,
zinc treatment reduces several actions of STZ, including hypoinsulinemia and elevated blood glucose.
Therefore zinc can be protective even without induction of MT. In this study we utilized a far more
specific approach than zinc pretreatment to elevate MT in pancreatic beta cells. Therefore the results of our
study clearly confirmed the original suggestion that MT can protect B-cells.

In conclusion, for this part of study, we demonstrated that elevated activity of ROS scavengers is
beneficial for beta cell survival after exposure to oxidative stress. This result has potential therapeutic
values for diabetes therapy. First, overexpression or pretreatment with antioxidant compounds or proteins
on cultured islets may produce a donor islet highly resistant to ROS damage for islet transplantation.
Several studies have demonstrated that this is a feasible approach to improve the chance of successful islet
transplantation. Pretreatment with a SOD mimic compound significantly preserved cultured islet mass
(Bottino et al. 2002) and gene transfer of MnSOD by adenovirus remarkably extended islet graft function
in diabetic NOD recipient (Bertera et al. 2003). Second, induction of the endogenous antioxidant genes
may provide an alternative strategy for producing a more robust B-cell, without the need to insert foreign
genes. Many beta cell antioxidant genes such as MnSOD, thioredoxin and MT, are inducible. Pretreatment
with some agents such as glucocorticoids is able to increase antioxidant expression by over 10-fold in some
cell types (Palmiter et al. 1993). This increase is similar to the 4- to 30-fold increases we obtained with our
trans gene. Therefore, developing and applying a specific reagent to induce beta cell antioxidants might be a
valuable approach for clinic diabetes treatment.
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However, in this part of the study we only focused on ROS scavenging property of these antioxidant
transgenes. Neither in vitro exposure to ROS producing compounds nor in vivo production of STZ diabetes
closely resembles human Type 1 and Type 2 diabetes. The results from this part only suggest that the
pancreatic beta cells in our transgenic mice become resistant to ROS damage. Cytokines may be more
important mediators for beta cell death in Type 1 diabetes. Therefore, in the next part of this project we
studied the potential role of antioxidant transgenes in cytokine mediated beta cell dysfunction and cell
death.
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Figure 3-1. Superoxide radical in dispersed MnSOD, catalase

(Cat), MnSOD plus catalase

(MnSOD+Cat) transgenic and control FVB islet cells. ROS production was measured with oxidant
sensitive fluorescent probe CM-H2DCFDA as described in Materials and Methods. Cells were treated with
vehicle containing ImM NaOH (panel A), or I mM hypoxanthine (dissolved in ImM NaOH) plus 2 mU
xanthine oxidase (panel B), or I mM hypoxanthine plus 10 mU xanthine oxidase (panel C). Either
catalase and MnSOD alone or combination of MnSOD and catalase decreased islet cell superoxide radical
generated from the reaction of hypoxanthine and xanthine oxidase. Data were calculated from three or four
independent measurements. Vertical bars represent standard error.
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Figure 3-2, ROS production in dispersed MnSOD, catalase

(Cat), MnSOD plus catalase

(MnSOD+Cat) transgenic and control FVB islet cells after treatment with SIN-I. ROS production was
measured with oxidant sensitive fluorescent probe CM-H2DCFDA as described in Materials and Methods.
Cells were not treated (panel A), or treated with SIN-l 30 J..lM (panel B) and 100 J..lM (panel C). Either
catalase or MnSOD remarkably decreased ROS production in islet cells. MnSOD plus catalase reduced
ROS in islet cells more potently than either single transgene, indicating a synergistic action ofMnSOD and
catalase to dispose of SIN-l induced ROS production. Data were calculated from three or four independent
measurements. Vertical bars represent standard error.
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Figure 3-3, ROS production in dispersed MnSOD, catalase

(Cat), MnSOD plus catalase

(MnSOD+Cat) transgenic and control FVB islet cells after treatment with H 20

2,

ROS production was

measured with oxidant sensitive fluorescent probe CM-H2DCFDA as described in Materials and Methods.
Cells were not treated (panel A), or treated with H20 2 20 f..lM (panel B) and 100 f..lM (panel C). Either
catalase or MnSOD plus catalase remarkably decreased ROS production in islet cells. However, MnSOD
alone increased DCF signal, indicating more ROS were produced in MnSOD transgenic islet cells after
treatment with H20 2. Data were calculated from three or four independent measurements. Vertical bars
represent standard error.
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Figure 3-4. Cell viability in MnSOD, catalase

150

200

250

(~M)

(Cat), MnSOD plus catalase

(MnSOD+Cat)

transgenic islets and control FVB islets after treatment with H 20 2 for 12 hours. Islet cell viability was
calculated as percentage of control islet cell metabolism indicated by Alamar Blue absorbance as described
in Materials and Methods. Data were mean ± SE from four independent measurements. Vertical bars

represent standard error.

* P<O.05 and ** P<O.Ol

between the indicated transgenic islets and FVB control

islets at the corresponding concentration of H20 2 by two-way ANOV A. Either catalase alone or MnSOD
plus catalase significantly reduced H20 2 induced islet cell death. But MnSOD alone sensitized H20 2
toxicity to islet cells at the lowest concentration of H20 2 •
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Figure 3-5. ROS production in dispersed FVB control and transgenic HMT-l islet cells. ROS
production was measured with oxidant sensitive fluorescent probe CM-HzDCFDA as described in
Materials and Methods. Islet cells were not treated (panel A), treated with J 00 !-lM H202 (panel B),
treated with 30 !-lM SIN-J (panel C), treated with J mM hypoxanthine plus 2 mU xanthine oxidase (panel
D). The solid circles indicate FVB control islet cells. The open circles indicate HMT-J transgenic islet
cells. This figure is typical of three independent experiments. This work was accomplished by Xiaoyan Li
in our laboratory.

65

B

A
SN AP
(mM)

[

"
~~

-

0-

0

25
20

.

__e_FVB

-

- HMT-1

~
a.~

0

-

a.
!l
_
0

«.
o •
-ll

.

15
10

i;j ~

"n
- ,.•
~

~

,

5

....

**

,-

*

0
J

2

0

SNAP (mM)

;;-

'60

_ _ FVB

m "E

'60

-

z

2

•-

0

~-

28:

~ i
~

'00
60

~

60

o
-"n
.. .

3

"
.E i •l

40

"•

20

"-

0

~

0

FVB

HMT-J

'40
120

.

- HMT-1

*~
.Jo2

0

J

SNAP (mM)

Figure 3-6. Nitric oxide induced damage in FVB a nd HMT-\ transgenic islets exposed to SNAP for
24 hr.

(A) Representative photomicrographs of FVB and MT is lets after SNAP treatment. The

concentrations of SNAP are shown on the left. Similar results were obtained in four independent
experiments. Magnification x 100. (B) Necrosis and apoptosis in SNA P treated islets. Ce ll death was
measured as described in Methods. Data were calc ul ated from four independent experiments.
indicate MT and FVB values were different at the same SNA P concentration

(P<0.05 and

re spectively by one-way ANOVA test). Vertical bars indicate standard error of the mean.
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Figure 3-8. Synergistic protection by MnSOD plus Catalase against STZ induced diabetes. Sex and
age matched transgenic and nontransgenic animals received a single high dose (220mglkg body weight) of
STZ via ip injection. Blood glucose levels were monitored daily for eight days following the injection.
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A

Figure 3-9. Nitrotyrosine staining in pancreatic islets from STZ treated animals. Transgenic and
control mice received an intraperitoneal injection of STZ at a dose of 220mglkg body weight. Pancreata
were removed after 30 hr and sections were stained with a polyclonal anti-rabbit nitrotyrosine antibody.
(A) FVB, (B) Cat, (C) MnSOD, (D) MnSOD+Cat. Combination of antioxidant transgene MnSOD and
Cata lase remarkabl y reduced STZ induced nitrotyrosine production in pancreatic islets. Similar results
were obta ined from 2 to 4 animals in each group. Magnification x 400.
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Figure 3-1 0. Photomicrographs of FVB a nd HMT- I islets after STZ treatment ill vitro . Both control
and transgen ic islets were treated with STZ as describe in Materials and Methods. The dose of STZ is
shown on the left. In HMT-I islets, MT overexpression reduced the disruption to morphology. Sim ilar
res ults were obtained in seven independent experiments. Magn ification X 200.
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Figure 3-11. Fragmentation of high-molecular weight DNA by STZ treatment in "VB and HMT-I
islets. The MT transge ne reduced DNA fragmentat ion. Islets were exposed to the indicated concentrations
of STZ for 18 hours. DNA was analyzed as described in Materials and Methods. Similar resulls were

obtained in seven independent experiments.
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CHAPTER IV
THE ROLE OF ANTIOXIDANT TRANSGENES IN TOXIC EFFECT OF CYTOKINES
ON PANCREATIC BETA CELLS

Introduction
Type 1 diabetes is an autoimmune disease, characterized by selective destruction of pancreatic beta
cells. In the early stage of the disease pancreatic islets are invaded with immune cells, a process termed
insulitis. A large body of evidence has emerged that proinflammatory cytokines, secreted from those
infiltrated macrophages and T-lymphocytes, are important mediators of beta cell functional disturbance and
cell death through necrosis and apoptosis (Eizirik et al. 1996; Rabinovitch 1998). In cultured beta cells,
including isolated murine, rodent and human islets, and insulin secreting cell lines, interleukin-l p alone or
interleukin-1 p combined with other cytokines inhibit beta cell insulin secretion, lower the synthesis of
insulin, protein and DNA, and finally cause beta cell death (Corbett et al. 1993; de-Mello et al. 1996;
Delaney et al. 1997; Flodstrom & Eizirik 1997; Heimberg et al. 2001; Iwahashi et al. 1996). The
detrimental effect of cytokines on beta cells is also reported in some animal models of Type 1 diabetes. In
the lymphocytic choriomeningitis virus

(LCMV)-induced diabetic model, LCMV induced beta cell

destruction and diabetes does not occur in mice that are interferon-y-deficient or that express a mutated
interferon-y receptor specifically in beta cells (Oldstone et al. 1991; von et al. 1997). This indicates the
importance of the cytokine interferon-y in the development of diabetes. Elevated beta cell expression of
cytokines and cytokine receptors has been found in NOD mice that spontaneously develop autoimmune
diabetes (Cardozo et al. 2003). Cytokines have also been shown to play important roles in beta cell damage
in other animal models of autoimmune diabetes such as BDC2.5 T-cell receptor transgenic models (Ji et al.
1999).
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The destructive effect of cytokines on beta cells is generally recognized to be induced in part by an
effect of NO that is produced by the inducible nitric oxide synthase

(iNOS) upon stimulation with

cytokines. Increased expression of iNOS and excessive NO production are seen in both cultured islets after
treatment with cytokines and beta cell infiltrated with lymphocytes in NOD mice (Suarez-Pinzon et at.
2001) and BB rats (Kleemann et at. 1993). Application of iNOS inhibitors benefits cultured beta cells
(Brandhorst et al. 2001) and prevented diabetes in a variety of animal models (Fukuda et at. 1995; SuarezPinzon et al. 2001). A target disruption of the iNOS gene provided partial protection against diabetes in
mice treated with multiple low-dose STZ (Flodstrom et at. 1999). However, in some other studies cytokine
induced beta cell dysfunction and cell death were shown to be independent of the NO generation pathway
(Wu et at. 2001; Saldeen et al. 2001). In human islets pharmacological inhibition of iN OS activity failed to
prevent cytokine induced impairment of insulin secretion (Eizirik et al. 1994b; Welsh et at. 1994a). The
islets isolated from iNOS gene deficient mice still undergo apoptosis after cytokine treatment despite high
resistance to cytokine induced suppression of islet function (Liu et al. 2000a). Therefore cytokine induced
beta cell toxicity may involve multiple signal pathways (Saldeen et al. 2001; Saldeen et at. 2001; Andersen
et al. 2000).

The partial independence of cytokine toxicity to NO may be explained, at least in part, by cytokine
induced ROS generation in the beta cells. ROS and ROS derived lipid oxidation have been found in
cultured rat (Rabinovitch et al. 1992) and human islets (Rabinovitch et al. 1996) after cytokine treatment.
In NOD mice beta cell destruction is found to be partially mediated by reactive oxygen intermediates,
including peroxynitrite (Horio et at. 1994; Suarez-Pinzon et al. 1997). Those ROS cooperatively enhance
NO mediated beta cell toxicity (Tiedge et al. 1999). Therefore, some laboratories have tested the potential
effect of antioxidant enzymes or compounds against cytokine toxicity to beta cells. In insulinoma RINm5F
cells (Lortz et at. 2000; Tiedge et at. 1998) and INS-l cells (Moriscot et at. 2003; Hohmeier et at. 1998)
elevated antioxidant proteins, such as catalase, glutathione peroxidase, CU/Zn SOD or MnSOD conferred
protections against cytokine mediated toxicity. But their data were not completely consistent because one
group reported the protection of MnSOD against interleukin-l ~ was through the reduction of NO
(Hohmeier et at. 1998), presumably due to reduced iNOS expression, while the other report showed the
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protection by these antioxidants was unrelated to iNOS expression (Lortz et al. 2000). External application
of antioxidant

~nzymes

or compounds also showed conflicting results; in some studies ROS scavengers

were protective against cytokine toxicity, whereas in other reports there was no protective effect (de-Mello

et al. 1996; Welsh et al. 1994b). Therefore, it still remains uncertain whether antioxidant treatment is
beneficial for pancreatic beta cells exposed to cytokines. Moreover, no study has been carried out to test
whether the constant increase of antioxidant expression in a transgenic animals could protect primary beta
cells from cytokines even though a transgenic mouse model with CulZn-SOD overexpression, which is
resistant to alloxan induced diabetes, was established in 1997 (Kubisch et al. 1997).

Therefore, in this part of study we used our transgenic mice to further investigate the potential effect
of antioxidants, catalase, MnSOD, and MT on cytokine induced beta cell destruction in isolated primary
mouse pancreatic islets. Since our antioxidants were expressed in real beta cells rather than insulinoma cell
lines and the expression is permanent and within the cell, our results are not subject to many of the
limitations of earlier studies. Our result showed that none of these antioxidants conferred any benefit at all
to pancreatic mouse islets after exposure to cytokines.
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Materials and Methods

Islet insulin secretion after cytokine treatment: Cytokine treatment and followed insulin secretion
assay were carried out on 96-well tissue-culture plates. In each well 10 islets were incubated in 200 /-ll
culture medium in absence or presence of different concentrations of cytokines (mouse recombinant
interleukin-I p plus interferon-y, Sigma, St. Louis, MO) for 18 hours. After incubation, islets were rinsed
with 3mM glucose modified KRB buffer twice. Static islet insulin secretion was performed by stimulation
in 20 mM glucose modified KRB solution, and secreted insulin level was measured with the procedure as
stated in MATERIALS AND METHODS OF CHAPTER II (Page 25).

Islet cell viability after cytokine treatment. Islet cell viability was indicated by islet cell metabolic
activity that was measured with Alamar Blue, as described in MATERIALS AND METHODS OF PART
II. In detail, fifteen overnight-cultured islets were hand picked into 200 /-ll fresh culture medium (no
phenol red) containing 1:20 diluted Alamar Blue in a 96-well microplate. A pre-treatment 4-hr metabolic
activity of the islets was measured for normalizing the post-treatment islet metabolic activity. After three
washes of fresh culture medium (no phenol red), islets were cultured for six days in 200 /-ll culture m;dium
(no phenol red) supplemented with or without varying concentrations of cytokines (mouse recombinant
interleukin-l p plus interferon-y). Every other day 100 /-ll culture medium was replaced with 100 /-ll fresh
culture medium (no phenol red) containing cytokines, thereby no change of final cytokine levels. In the
end of treatment, 50 /-11 culture medium was replaced with 50 /-11 fresh culture medium containing 1:5
diluted Alamar Blue, for a final dilution of 1:20. The color was developed for another 4 hr and the
fluorescence was measured again. A fluorescent value from the "blank well", which contained no islets but
exactly followed the above procedure with highest level of cytokine treatment, was deducted from all other
fluorescent values. Islet cell viability was calculated as the ratio of fluorescence after treatment to the
fluorescence before treatment. The untreated islet cell viability was arbitrarily set as 100%.

Measurement of nitrite formation: Nitrite formation was measured in islet culture medium as an
indication of cytokine-induced NO production, as previously described
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(Hohmeier et

at.

1998). The

treatment of cytokines was performed on 96-well tissue-culture plates. For each well 40 to 50 overnightcultured islets were cultured for 24 hours in 170 Jll islet culture medium (no phenol red) with or without
cytokines (mouse recombinant

interleukin-l~

plus interferon-y). After incubation, the culture media were

collected, and 150 III of culture medium was reacted with 150 III of Griess reagent (Molecular Probes,
Eugene, OR) at room temperature for 30 min. The optical density was read at 550 nm using a Tecan
(Durham, NC) plate reader. Nitrite concentration was calculated using a sodium nitrite (Sigma, St. Louis,
MO) standard curve prepared in islet culture medium (no phenol). Data were normalized to total islet DNA
determined by picogreen DNA assay (Molecular Probes, Eugene, OR).

Islet iN OS expression after cytokine treatment. The messenger RNA level of iNOS in cultured
islets was measured by real-time quantitative RT-PCR. Eighty to one hundred overnight-cultured islets
were treated without or with cytokines (mouse recombinant interleukin-l ~ 5 Vlml plus interferon-y 100

Vlml) in 300 Jll culture medium for six hours in 1.5 ml microtubes. After treatment islets were rinsed with
fresh HBSS solution twice and islet total RNA was extracted with an RNA preparation kit from Stratagene
(Absolutely RNA Microprep Kit, Stratagene, La Jalla, CA) according to the manufacturer instructional
manual. The RNA sample was treated with DNase to remove all traces of genomic DNA contamination
and its concentration was determined by Ribogreen RNA quantification kit (Molecular Probes, Eugene,
OR). Fifty ng total islet RNA was reverse-transcribed to cDNA with a StrataScript reverse transcriptase
(Stratagene) in the presence of oligo dT based on the manufacturer provided procedure.

Real time

quantitative PCR was prepared using Brilliant™ plus Two-Step Quantitative RT-PCR Core Reagent kit
(Stratagene) and executed using Mx4000TM real-time multiplex quantitative PCR system (Stratagene). The
cDNA sequences for murine

~-actin

and iNOS were obtained from GenBank, and the primer and probe

sequences were designed using Primer3 software (Steve Rozen and Helen 1. Skaletsky (2000) Primer3 on
the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics
Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365-386). To avoid

amplification of genomic DNA, the primer-probe sets were designed to span exon-exon boundaries. The
probes were labeled with a fluorescent reporter 6-carboxyfluorescin (FAM) at the 5' end and a quencher,
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6-carboxytetramethylrhodamine (TAMRA) at the 3' end. The sequences for the primer-probe sets for
each gene were as follows: iNOS

(forward

5'-GTAGCCAGCGTACCGGATGA-3', reverse 5'-

CAACATCAGGTCGGCCATCAC-3', probe 5'- CCCCAGCGGACTGACGGCAAACAT-3'); f3-actin
(forward 5'-ATGGCTGGGGTGTTGAAGGT-3', reverse 5'-TACAATGAGCTGCGTGTGGC-3', probe
5'- CACCCTGTGCTGCTCACCGAGGC-3'). PCR amplifications were performed in a total volume of25
Ill, containing 1 III of cDNA sample (transcribed from -50 ng total islet RNA), 900 11M of each primer,
250 11M of the corresponding probe, 2.0 III of GAUC mix (200 11M each of dA TP, dCTP and dGTP, but
400 /lM of dUTP), 0.Ql Ullll Uracil-DNA-N-glycosylase

(UNG), 0.05 UlIlI of SureStart Taq DNA

polymerase, 1x core PCR buffer, 5.5mM MgCh. For each reaction, UNG reaction was processed at 50°C
for 2 min followed a polymerase activation step at 95°C for 10 min, then amplification was executed by
alternating between 95°C for 15 s and 60°C for 60 s for 40 cycles. The sample iNOS and f3-action mRNA
levels were calculated respectively from standard curves of iNOS and f3-actin using FVB control islets
exposure to mouse recombinant interleukin-l f3 50 U/ml plus interferon-y 1000 U/ml for 6 hours. Data were
expressed as folds of iNOS expression over f3-actin expression.

Data analysis: Data are presented as the mean ± standard error. Statistical analysis was performed by

one-way or two-way ANOV A and Dunnet's post hoc

(2-taiIed) test. Computations were carried by

statistical programs from SPSS (version 10.0) and Sigmastat (version 2.03).
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Results

Neither MnSOD nor catalase protected pancreatic islets from cytokine cytotoxicity. It is well
established that inflammatory cytokines suppress pancreatic beta cell insulin secretion and lead to cell
death through necrosis and apoptosis (Eizirik et al. 1996; Eizirik & Darville 2001). In this study both beta
cell function of insulin secretion and cell viability were assessed in cultured control FVB and transgenic
islets after exposure to cytokines. As shown in Figure 4-1, cytokine treatment

(interIeukin-l ~ plus

interferon-y) caused a drastic inhibition of islet insulin secretion. However neither the MnSOD nor catalase
trans gene reversed this suppression at any concentration of cytokine tested. Instead of having synergistic
protection against STZ and peroxynitrite as demonstrated in Part II, combination of MnSOD and catalase
did not provide pancreatic islets with any resistance to cytokine induced beta cell toxicity as revealed by
both islet insulin secretion (Figure 4-1 A) and islet metabolic activity (Figure 4-lB).

Cytokine mediated destruction of pancreatic beta cells is accompanied by activation of iNOS
expression and production of NO. MnSOD and antioxidant compounds have been shown to inhibit iNOS
activation and NO production in insulin secreting cell lines after cytokine treatment. Therefore we further
measured iNOS expression levels by real time quantitative RT-PCR and NO production by the Griess
reaction in islets exposed to cytokines. None of the beta cell antioxidant transgenes, including MnSOD,
catalase or MnSOD plus catalase was able to decrease cytokine induced activation of iNOS expression
(Figure 4-2) and NO production (Figure 4-3) at every concentration of cytokines we examined. These data
indicate no protective effect of MnSOD and catalase against cytokine cytotoxicity in primary mouse beta
cells.

MT did not protected pancreatic islets from cytokine cytotoxicity. We carried out similar studies
on MT transgenic islets exposed to cytokines. MT seemed a promising candidate for protection from
cytokines since MT is a potent NO radical scavenger as demonstrated by our own and other laboratories
(Cai et at. 2000; Kennedy et at. 1993). However, our data showed that the MT trans gene also failed to
provide protection against cytokine induced beta cell toxicity. After cytokine treatment the inhibition of
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glucose stimulated insulin secretion (Figure 4-4) and stimulation of NO production (Figure 4-5) were the
same in control FVB and HMT-I transgenic islets. Therefore, our data suggest, unlike the data from insulin
secreting tumor cell lines, that ROS may not mediate cytokine induced cytotoxicity in real beta cells.
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Discussion

In this part of study, we investigated the potential role of antioxidant transgenes against cytokine
toxicity to pancreatic islet cells. The data showed that none of the antioxidant trans genes we tested,
including MnSOD, catalase, MnSOD plus catalase, and MT, was able to protect from cytokine toxicity
revealed by measurements of glucose stimulated islet insulin secretion, islet cell metabolic activity, iNOS
expression and NO production in culture islets exposure to cytokines. Our results imply that antioxidant
proteins do not alter cytokine toxicity in primary mouse beta cells.

Proinfiammatory cytokines are important destructive mediators causing pancreatic beta cell death in
various species, including human, rat and mouse (Eizirik et al. 1994b; Cardozo et al. 2001; Eizirik et at.
1994b; Rabinovitch et at. 1992; Utsugi et at. 1996). A variety of studies have demonstrated that IL-1 ~
alone is able to provoke dysfunction of beta cells and finally lead to cell death (Ling et at. 2000). The effect
of IL-1 ~ is potentiated by combination with other cytokines such as interferon-y and tumor necrosis factor-

a (Eizirik et at. 1996). Induction of MnSOD, heat shock protein 70, and heme oxygenase and iNOS are
commonly seen in pancreatic beta cells exposed to cytokines (Andrade et at. 1996; Ling et at. 2000;
Strandell et at. 1995). As a consequence of iNOS induction intracellular production of NO is greatly
increased. NO is considered to be a major culprit leading to beta cell death, although there are several
studies showing NO is not involved in beta cell apoptosis after cytokine treatment (Liu et at. 2000a; Ling et

at. 2000; Saldeen et al. 2001). In addition, experimental evidence indicates that ROS are generated in
cytokine-stimulated beta cell via unknown mechanisms (Horio et al. 1994; Rabinovitch et at. 1992).
Therefore studies have been performed to show that overexpression of antioxidants in insulin secreting cell
lines resulted in a significantly higher resistance against cytokines and NO mediated cytotoxicity. Stable
overexpression of MnSOD in INS-1 and RIN1046-38 cells (Hohmeier et at. 1998) provided complete
protection against

IL-1~

toxicity via the inhibition of NO production. In RIN5mF cell lines, overexpression

of catalase, glutathione peroxidase and Cu/Zn SOD prevents cell viability loss caused by cytokine mixtures
(Azevedo-Martins et at. 2003; Lortz et at. 2000; Tiedge et at. 1999). However our results totally disagreed
with these results showing protection of beta cell lines from cytokines by antioxidants.
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The reason for the discrepancy between our results and other labs results is uncertain. The simplest
explanation is that our primary mouse beta cells (real beta cells) have a different response pathway to
cytokine induced damage than exists in beta cell tumor lines (abnormal beta cells). Our results indicate
that ROS are not involved in the cytokine response of "real", primary beta cells. The results of other labs
indicate that ROS are involved in the response of "artificial" tumor beta cell lines.

However, this

interpretation could be overly simplistic. Recent studies, consistent with some of our results in the next
section, suggest that ROS are involved not only in cell destruction but also in activation of cell protective
pathways (Kamata & Hirata 1999; Forman et al. 2002). Thus an alternative explanation for our failure to
see protection from cytokines by antioxidants is that our antioxidant transgenes prevent cell protective
pathways from being turned on by ROS.

Our antioxidant response could be a combination of ROS

protection from cytokines and inhibition of cell protection pathways. The net effect may be that we saw no
benefit of antioxidants in the preceding studies. At this time this is of course, speculative.
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Figure 4-\. G lucose stimu lated insulin sec retion and cell viability in control "VB and transgenic
islets after cytokine treatment.

(A) Isolated islets were treated with indicated concentrations of

interleukin- Ip (IL- I) and in te rferon-y (IFN) for 18 hours . Basal (3 mM glucose, data not shown) and

20mM glucose stimulated islet insu lin secretion were measured with coated tube RIA ki t as described in
the Methods. (B) Cell viahility in cu ltured islets after 6 days of cytokinc treatment. Ce ll viability was
measured by Alamar Blue assay.

Data were calculated ITom four independent measurements of two

experiments in each group. Neither single transgene (MnSOD or Catalase) nor combination of Mn SOD
and Catalase preve nted ITom cytokine induced islet cell insulin secretion dy sfunction and cell death.
Vertical bars show the standard error of the mea n.
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CHAPTER V
THE ROLE OF ANTIOXIDANT TRANS GENES IN TYPE 1 DIABETES OF NOD MICE

Introduction

Several models are available to study human Type 1 diabetes. NOD mice and Bio-Breeding (BB) rat
spontaneously develop autoimmune diabetes (Leiter et at. 1987b; Maclaren et al. 1983). Another model,
multiple low dose administration of STZ model (Shimizu et al. 1991) is the most rapid and convenient
way to produce autoimmune diabetes. In this model animals receive up to five STZ injections at a very low
dosage (40 to 60 mg/kg) (Flodstrom et at. 1999). Such low doses of STZ initially cause a limited damage
to pancreatic beta cells, which activates the immune system and triggers a late, massive immune
destruction of beta cells, resulting in autoimmune diabetes. However, this model is inappropriate in our
project since all of our antioxidant transgenes; MnSOD, catalase and MT are able to protect from STZ. Due
to this protection it becomes impossible for us to discriminate whether the potential protection from
multiple low doses of STZ by catalase, MnSOD or MT comes from the protection against immune attack
or from the direct protection against STZ itself. Therefore, in this study the NOD mouse model for Type 1
diabetes was chosen for investigation of the potential effects of antioxidant trans genes against Type
diabetes.

NOD mice have been accepted as one of the best models of human autoimmune Type 1 diabetes. In
this strain, both female and male NOD mice develop diabetes spontaneously, but the females are more
susceptible. In the female mice the incidence of diabetes is 90-100% by 30 weeks of age. Male mice
develop diabetes at a frequency of 40 to 60% by 30-40 weeks of age (Leiter et al. 1987b). This strain of
mice was first reported in 1980 (Makino et al. 1980) and now it has been recognized to have very similar
features to human Type 1 diabetes. Before becoming overtly diabetic, with non-fasting plasma glucose
higher than 250 mgldl, NOD mice go through a long, clinically silent period characterized by a leukocytic
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infiltrate of the pancreatic islets, referred to as insulitis. This insulitis phase is also present in prediabetic
human patients. As early as 12 weeks of age a marked reduction of pancreatic insulin contents occurs in
female mice, and a few weeks later in males, due to a selective destruction of pancreatic islet beta cells.
The destruction to beta cells is a progressive process mediated by autoimmune reaction involving
inflammatory cells, cytokines, and autoantibodies. All of these processes are very similar to human Type 1
diabetes (Leiter et al. 1987b; McAleer et al. 1995).

Susceptibility to Type 1 diabetes in NOD mice is polygenic. Currently at least 20 diabetic susceptible
alleles have been identified that are associated with the onset and development of diabetes in the NOD
mouse (Adorini et al. 2002). These alleles are highly polymorphic. This makes it possible to identify the
diabetic susceptible alleles with the aid of microsatellite markers, a group of variable DNA sequences
closely linked to the diabetic susceptibility loci. By genotyping these diabetic susceptible alleles, Serreze et
al.. (Serreze et al. 1996) established a successful protocol for producing "speed congenic NOD mice" from

other strains of mice. In his procedure, a transgenic FVB mouse was continuously backcrossed to NOD
mice for four generations. From the fourth generation, the transgenic litters were assessed for
homozygosity of 15 diabetic susceptible alleles by standard PCR using a series of microsatellite markers.
Serreze et al. found that five backcrosses were sufficient to obtain one animal homozygous for all of 15
diabetic susceptible alleles. This animal was used as the progenitor to breed with NOD mice to produce
offspring with greater identity to NOD mice. Since our antioxidant transgenic mice were established and
maintained on the FVB background strain, we utilized Serreze's procedure to more rapidly generate new
NOD strains homozygous for all NOD susceptibility alleles which were congenic for our pancreatic beta
cell antioxidant trans genes.

The susceptibility to Type 1 diabetes in NOD mice is also significantly affected by environmental
factors, including housing conditions, health status, diet and chemical or virus exposure. The onset of
diabetes in NOD mice is relatively slow and random. The onset of diabetes in NOD mice is known to be
highly variable from one mouse to another. Therefore cyclophosphamide (CYP), an alkylating cytostatic
drug is often employed to speed up diabetes onset in NOD mice (Harada & Makino 1984). The mechanism
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for this accelerated diabetes by CYP is not completely defined but in some studies CYP has been shown to
activate immune response in NOD mice by suppressing T-helper cells (Yasunami & Bach 1988). In this
project we injected CYP into our transgenic NOD mice to accelerate and synchronize NOD diabetes.

Some others laboratories have used NOD mice to show the protective effect of antioxidant
compounds in prevention of diabetes (Fukuda et al. 1995; Hotta et al. 1998). But the results from those
studies are ambiguous since the antioxidant chemicals they used have multiple actions and have no
specificity to the beta cell. The beneficial effect exerted by those antioxidants against NOD diabetes could
come from actions on other organs, such as immune system, rather than a direct protective action on beta
cells. One other antioxidant protein, thioredoxin (Hotta et al. 1998), has been specifically expressed in
pancreatic beta cells. This produced a significant protection against NOD diabetes. However, thioredoxin
has multiple actions in addition to being an antioxidant (Saitoh et al. 1998). Therefore to answer whether
beta cell antioxidant protection is beneficial to prevent autoimmune diabetes, it is crucial to use more
specific antioxidant proteins with more defined expression in the beta cell. Our transgenic models meet
these requirements because the antioxidant proteins are expressed uniquely in beta cells, and the ROS
scavenging effects of these antioxidants are efficient and specific.
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Materials and Methods

Maintenance of NOD mice and generation of transgenic NOD strain congenic for transgenes:
NOD mice, purchased from Jackson Laboratory

(Bar Harbor, Maine), were housed in individually

ventilated micro isolator cages at the Research Resource Center in University of Louisville. Strict cage
changing and animal handling procedures were carried out to minimize viral infection. The standard
mouse chow was Laboratory Rodent Diet 5001 (PMI Feeds, St. Louis, MO) containing 23% protein and
4.5% fat. This diet was suitable for maintaining a high incidence of diabetes in NOD mice. Transgenic
NOD mice with beta cell specific expression of catalase and MT were generated from our transgenic FVB
mice using a speed congenic procedure described by Serreze, et al. (Serreze et al. 1996). In details, the MT
and catalase transgenic FVB mice were backcrossed to NOD mice for up to 10 generations. Since the 5th or
7th generation, PCR based genotyping with the aid of microsatellite markers was performed to find a
founder animal congenic for both transgene and all 19 NOD diabetic susceptible alleles. This animal was
used as the progenitor for additional one or two backcrosses to NOD mouse for more homozygosity of
NOD mouse genome. The produced transgenic and nontransgenic NOD offspring were intercrossed to
generate animals which were used in this study.

peR typing of NOD diabetes loci: The appropriate PCR primer pairs for polymorphic microsatellite

markers of diabetic susceptible alleles of NOD mice were based on the report of Serreze et al (Serreze et
at. 1996) and the Mouse Genome Database in Jackson Laboratory. Those primers were purchased from

Research Genetics and listed in Table 5-1. Mouse tail DNA was extracted from transgenic NOD offspring
and control FVB and NOD mice with Qiagen DNAeasy Kit (Qiagen, Valencia, CA) according to the
manufacturer instructional manual. PCR reaction was performed in a 20 III volume containing 1.5 III
sample DNA (about 20ng DNA), 200 IlM dNTP, 0.2 IlM of each primer, 0.45 unit of Platinum Taq DNA
polymerase, 16 mM

(NH4)2S04, 67 roM Tris-HCl, pH 8.8, 0.01% TWEEN-20, and appropriate

concentrations ofMgCl 2. MgCh concentrations were varied between 1 and 5 mM based on different primer
sets (Table 5-2). PCR reaction was carried out in an Eppendorfthermocycler equipped with a heated hood.
The reaction contained a first polymerase activation step at 95°C for 2 min, followed with 32 cycles of
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amplification, and ended with an extenstion step at

noc for 7 min.

Each amplification cycle consisted of

45 seconds of denaturing at 94°C, 45 seconds of annealing at 57°C and 1 min of extension at

n°c.

PCR

products were fractionated on 6% NuSieve (FMC) agarose/TAE and stained with 0.5 Ilg/ml ethidium
bromide. Control PCR reactions of inbred FVB and NOD mouse DNA were exerted every time and were
fractioned in parallel to PCR products from other samples in order for a clear-cut discrimination of NOD
diabetic allele from FVB normal allele. The PCR Mg2+ concentration and approximate size of PCR
products from FVB and NOD strains for each set of micro satellite markers were summarized in Table 5-2.

H&E staining and immunostainingfor MT: Transgenic or control mouse pancreas was fixed in 10%
formaldehyde in 0.1 M phosphate buffer (pH 7.2), dehydrated in an ascending graded series of ethanol and
subsequently infiltrated with paraffin. Serial sections were cut at 5Jlm, mounted on polylysine coated
slides. Slides were stained with hematoxylin and eosin with a standard protocol. MT immune staining was
carried out with a procedure as described in Materials and Methods of Part II, except that 3, 3'diaminobenzidine (DAB) was used as the chromagen.

Cyclophosphamide administration and diabetes monitoring: Age and sex matched transgenic and
nontransgenic NOD mice received two doses of intraperitoneal injection of 200mg/kg body weight of
cyclophosphamide. The first and second injections were two weeks apart. The mouse tail blood glucose
level was monitored using a glucose meter (OneTouch Ultra, Life Scan) every other day after first
injection of CYP. Mouse was considered diabetic after two consecutive readings of blood glucose over 200
mgldl. The onset of diabetes was dated from the first of these two sequential measurements. Some mice
were sacrificed after 8 days of CYP injection. Pancreas was removed for pancreatic insulin measurement,
histology and immunohistochemistry study.

In vivo CYP administration to FVB mice: Two groups of transgenic HMT-I and control FVB mice
were used with age and sex ratio matched with above study in NOD mice. In one group, both transgenic
and control FVB mice received two doses of intraperitoneal injection of 200 mg/kg body weight of
cyclophosphamide, as did in the NOD mice. The first and second injection were two weeks apart. Another
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group of mice received a single intraperitoneal CYP injection at a dose of 380 mglkg body weight. After
CYP injection, mouse tail blood glucose level was monitored using a glucose meter (One Touch Ultra, Life
Scan) every other day. After 30 days for the group injected with low dose of CYP and 9 days for the group
injected with high dose of CYP, mice were sacrificed and the pancreata were removed for measurement of
preserved pancreatic insulin content.

Purification of mouse liver microsome (Devanesan et al. 1999). Normal FVB mouse was treated
with cyclophosphamide

(300 mg/kg body weight, ip.) for 2 days for induction of liver microsome

enzymes. The mouse liver was removed and homogenized in 3 volume of precooled Tris-KCl Buffer
(20mM Tris-HCl, pH 7.4, 0.15 M KCI). The homogenate was centrifuged at 9,000x g for 20 min at 4°C.
The supernatant was centrifuged at 105,000x g for 1 hour at 4°C to obtain microsome pellet. After two
washes with precooled Tris-KCl buffer, microsome pellet was resuspended in I ml Tris-KCl buffer
followed by a passage through 0.45 f.lM filter. The filtered solution was determined by Pierce BCA protein
assay kit for protein concentration and was then stored at -70°C for next use.

In vitro CYP treatment on FVB islets: Assessment of CYP cytotoxicity to islets was carried out in a

96-well microplate with a modified procedure of Meyer et al. (Meyer et al. 1997). Ten overnight cultured
HMT-I transgenic or control FVB islets were incubated for 5 hr in 200 f.ll culture medium (pH 7.4)
containing 4mM NADP+, 4mM glucose-6-phosphate, 2 mU/ml glucose-6-phosphate dehydrogenase, 75
f.lg/ml liver microsome and appropriate concentrations of cyclophosphamide as indicated in the figure.

After cyclophosphamide treatment, the culture medium was replaced with 200 f.ll fresh culture medium and
islets were incubated for another 16 hr. After incubation, both islet morphology and islet DNA content
were analyzed.

Data analysis: The cumulative incidence of diabetes was calculated for each group and the
significant difference was tested by Kaplan-Meier survival test using SPSS program (version 10.0). Two-
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way ANOVA and Dunnet's post hoc (2-tailed) test were used to test the difference between transgenic and
control NOD mice before and after CYP treatment.

Results

Production of transgenic NOD mice congenic for MT or catalase transgene: In this study, so far,

lines on the NOD background with beta cell specific overexpression of antioxidants MT (designated
MTNOD), and catalase (designated CatNOD) were derived from our FVB transgenic mice. The MnSOD
transgene has been bred for several generations onto NOD mice but the MnSODNOD mice have not been
achieved. For MTNOD mice, the MT transgenic FVB mice were backcrossed to NOD mice five times. On
fifth generation, seven MT trans gene positive offspring were selected for PCR genotyping of 19 diabetic
susceptible alleles. The presence of the MT trans gene in these progenitors, tentatively identified by their
grayish coat color due to the co-injected trans gene tyrosinase, was confirmed with PCR for the MT
transgene. Two out of those seven mice were found homozygous for all 19 diabetic susceptible alleles
(Figure 5-1). These two mice were used as founders to breed with NOD mice one more time. Currently the
MT congenic NOD mice were maintained at the sixth generation by brother-sister breeding and these mice
were used in this study.

In addition to PCR, MT trans gene expression in pancreatic beta cells was also examined by

immunohistochemistry. Figure 5-2 shows MT immunostaining and H&E staining in pancreatic sections
from MTNOD and NOD mice that were euglycemic and 150 days old. Compared to NOD control islet
whose MT staining was negligible, MT staining was highly elevated in MTNOD islet. This expression of
MT was specific to pancreatic islets in that almost no staining could be seen in the exocrine pancreas. This
figure also showed that significant lymphocyte infiltration of pancreatic islets already occurred in both
MTNOD and NOD prediabetic mice at 150 days of age

(Figure 5-2, C and D), indicating the MT

transgene did not prevent insulitis. Therefore these MTNOD mice should be useful to test MT induced
resistance to Type 1 diabetes.
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For CatNOD mice, PCR analysis of homozygosity of all 19 diabetic susceptible alleles was started in
the offspring at the 7th generation of backcrossing of catalase FVB mice to NOD mice. But it was not until
the 9th generation that one mouse carrying the catalase transgene was found to be homozygous for all 19
diabetic susceptible alleles (data not shown). This mouse was backcrossed to NOD again. The offspring
were intercrossed to maintain the line and produce transgenic and nontransgenic littermates used in this
study. Similar to MTNOD, the CatNOD mice could be easily identified from their control littermates by
coat color because of the second transgene, tyrosinase. However the presence of catalase transgene in that
founder CatNOD mouse was also confirmed with PCR.

The effect of the MT transgene on NOD diabetes. Using these MTNOD and CatNOD mice we
tested the potential effect of beta cell antioxidant transgenes on NOD diabetes. Fifteen MTNOD and 16
control NOD mice were injected with cyclophosphamide twice (at days 0 and 14) at a dose of 200 mglkg.
After first injection diabetes onset and incidence were determined by the occurrence of hyperglycemia. To
our great surprise, the MT trans gene remarkably speeded up NOD diabetes (Figure 5-3) (P<O.OOI by
Kaplan-Meier survival analysis and Mantel-Cox Log-rank test), instead of delaying the onset of diabetes as
we had hypothesized. In control NOD mice, diabetes generally did not occur until 22 days after the first
injection of CYP. However in most MTNOD mice diabetes developed around ten days after the first
injection ofCYP.

This accelerated diabetes onset was confirmed by measurement of pancreatic insulin levels in control
NOD and transgenic MTNOD mice before and 8 days after CYP injection. As shown in Figure 5-4, the
pancreatic insulin content in MT transgenic and control NOD mice was similar before CYP injection.
However, 8 days after CYP injection the pancreatic insulin level in MTNOD mice was only 25% of their
original value before CYP injection; whereas the NOD control mice preserved almost 80% of their original
insulin. This indicated that a many more beta cells were destroyed in MTNOD mice than in NOD mice,
after CYP injection. Therefore these results suggest that MT overexpression in pancreatic beta cells makes
NOD mice more susceptible to CYP accelerated autoimmune diabetes.
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This is a very puzzling result, completely opposite to our original hypothesis: that ROS scavengers
would be helpful to prevent Type 1 diabetes. One possible explanation for this result is that the MT
transgene sensitizes pancreatic beta cells to direct CYP toxicity. If true, this sensitizing effect should also
be present in the FVB mice with beta cell overexpression ofMT. Therefore we went back to MT transgenic
FVB mice to test this possibility.

Protective effect of MT trangene against direct toxicity of CYP to pancreatic islets. To reveal
whether the MT trans gene increased direct CYP toxicity to beta cells, both in vivo and in vitro studies were
performed. CYP is an anticancer drug with a lethal dose of 500mg/kg in the mouse (Yan et af. 1991). In
FVB mice CYP does not induce autoimmune diabetes, as it does on the NOD background, therefore in
FVB mice any beta cell damage would be due to a direct effect of CYP on the beta cell. In the in vivo
study, two groups of FVB mice containing or not containing the MT trans gene were monitored for blood
glucose levels after CYP injection. But neither one single high dose nor two low doses of CYP injection
produced hyperglycemia in FVB and HMT-I mice (Figure 5-5). The blood glucose level in HMT-I mice
was similar to (at the low dose of CYP) or probably a little lower (high dose of CYP) than that in FVB
control mice. We also measured pancreatic insulin content in those mice one month (low dose of CYP)
and 9 days (high dose of CYP) after CYP administration. We found that pancreatic insulin levels of both
FVB and HMT -1 mice did not drop at all compared to the values from the animals without CYP injection
(data not shown). This indicates that CYP does not have a direct toxic effect on beta cells when
administrated in vivo.

However, activated CYP has indeed been shown to have a direct damaging effect on cultured cell
lines. It causes DNA alkylation and apoptotic cell death (Marks & Fox 1991; Sanderson & Shield 1996).
Therefore we also performed an in vitro study to test the potential effect ofMT on isolated islets exposed to
activated CYP. The activation of CYP was initiated by liver microsome extracts which contained P450
enzymes required for metabolism and activation of CYP. As shown in Figure 5-6, 0.5 mM CYP
significantly caused morphological disruption in control FVB islets, but much less damage in HMT-l
islets. Islet DNA quantification also showed that the MT trans gene significantly reduced islet DNA loss
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induced by activated CYP. MT induced DNA protection against CYP has also been shown in some cancer
cell lines (Parsons et

at.

1990; Wei et

at.

1999). These data suggest that the MT transgene protects beta

cells from direct toxicity of CYP, rather than sensitizing beta cells to CYP. The increased susceptibility to
CYP induced NOD diabetes by the MT trans gene is due to some other, still unidentified reason (s). But the
similar result obtained with our other antioxidant, CatNOD line

(see results below) suggests that

antioxidant activity is involved in sensitization to NOD diabetes.

The effects of catalase transgene on NOD diabetes. Unlike the MT protein that scavenges many
types of ROS, and also plays an important biological role in heavy metal homeostasis (Kumari et al. 1998),
catalase is an antioxidant enzyme with relative simple action to dispose of H20 2 . But interestingly, the
catalase transgene behaved very similarly to the MT trans gene in NOD mice. In Figure 5-7, eight CatNOD
and 11 control NOD mice were treated with cyclophophamide with the same procedure as used on
MTNOD mice. The data showed that the onset of NOD diabetes was significantly accelerated due to
overexpression of beta cell catalase (P<0.05 by Kaplan-Meier survival analysis and Mantel-Cox Log-rank
test). Again around ten days after the first CYP injection diabetes occurred in most CatNOD mice, whereas
most control NOD mice did not become diabetic until three weeks after the first injection of CYP.
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Discussion

In this part of our study, we produced two lines of transgenic NOD mice with elevated expression of
MT and catalase specifically in pancreatic beta cells. Both MT and catalase transgenes made the NOD mice
more susceptible to diabetes after CYP injection. The increased susceptibility was unlikely to be due to a
direct damaging effect of the transgenes since the transgenic NOD mice had very similar pancreatic insulin
level and islet morphology to control NOD mice. Also it was not due to a sensitization to direct CYP
toxicity to beta cells by antioxidant trans genes because in the FVB strain, MT was shown to be protective
against CYP. Our data suggest overexpression of antioxidant proteins in pancreatic beta cells increases the
susceptibility to NOD diabetes.

This finding is at great variance with previous studies that ROS scavengers might be beneficial for
beta cell survival during autoimmune diabetes. In NOD mice, increased formation of ROS and ROS
derived oxidative damage has been found present in pancreatic beta cells themselves and islet-invading
macrophages and lymphocytes (Horio et al. 1994; Suarez-Pinzon et al. 1997). Those ROS generally are
considered to be detrimental factors causing beta cell death in autoimmune diabetes. Our MT and catalase
trans genes can efficiently scavenge most types of ROS. But they actually exacerbate CYP accelerated
NOD diabetes. Consequently our results suggest that the ROS produced in the beta cells are not merely
detrimental factors leading to beta cell death in autoimmune NOD diabetes.

Extensive studies have been carried out showing the beneficial effects of antioxidant proteins.
MnSOD, Cu/Zn SOD, catalase, and glutathione peroxidase, as well as some other antioxidant compounds
have been shown to protect cultured cell lines or islets from exposure to ROS and cytokines (AzevedoMartins et al. 2003; Tiedge et al. 1997; Tiedge et at. 1998; Tiedge et al. 1999), and to reduce STZ and
alloxan induced diabete (Welsh et al. 1995; Grankvist et at. 1981a; Uchigata et at. 1982). However, many
of those studies were done in cell lines or on whole animals using systemic treatment of antioxidant
compounds; thereby none of those treatments closely mimic human or NOD autoimmune diabetes. Several
studies have demonstrated that injected antioxidant proteins or compounds protected both endogenous and
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transplanted islets in NOD mice (Bertera et at. 2003). But unlike our transgenes that were expressed only in
pancreatic beta cells, the other procedure for antioxidant protein delivery effects all cells in the body,
including the immune system. It is very possible that the protective effects observed with systemic
administration of antioxidants may come from effects on the immune system. In the literature three
transgenic animal models with beta cell specific expression of antioxidants have been described and tested
against autoimmune diabetes. In one model pancreatic beta cell expression of thioredoxin (Hotta et at.
1998) prevented NOD diabetes; however thioredoxin is also an antiapoptitic protein, apart from being an
antioxidant. In another model beta cell specific expression of extracellular SOD (Sandstrom et at. 2002)
failed to prevent spontaneous NOD diabetes. Our study is the first study to find increased susceptibility to
NOD diabetes due to antioxidant trans gene expressions in pancreatic beta cells. Because the same results
were obtained in two independent lines; catalase and MTNOD mice, the conclusion of increased
susceptibility should be reliable.

However, the reason for the increased susceptibility to NOD diabetes by antioxidants has not yet been
elucidated. In this study several possible artifacts have been ruled out: the prediabetic pancreatic insulin
content and islet morphology in MTNOD and CatNOD mice are the same as that in control NOD mice,
indicating no obvious damaging effect of the antioxidant transgenes; the antioxidant trans gene does not
sensitize to CYP toxicity directly in beta cells, in fact the MT transgene provides protection against CYP
direct toxicity to cultured islets. Currently we know transgenic MTNOD beta cells die more rapidly than
control NOD beta cells after cyclophosphamide injection. From these results we have a new hypothesis that
permanent expression of antioxidants suppresses beta cell survival processes by scavenging ROS. This
hypothesis and its background are discussed in greater details in the end of this dissertation, "Summary and
Direction for Future Studies".

In addition to our hypothesis, several other important mechanisms may need also be considered to
explain the increased diabetes susceptibility phenomenon. One possible mechanism is endoplasmic
reticulum (ER) mediated stress (reviewed in (Harding & Ron 2002; Oyadomari et at. 2002». The
pancreatic beta cells have a highly developed and active endoplasmic reticulum (ER) that leaves beta cells
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very susceptible to ER stress. Recent studies indicate that beta cell ER can sense and transduce apoptotic
signals from various genetic and environmental stressors. ER stress-mediated beta cell apoptosis plays an
important role in the development of diabetes. In our model, the overproduction of transgenic protein may
impose a significant stress burden on beta cell ER and promote beta cell apoptosis. To test this possibility,
we can measure the expression of some marker protein of ER stress in our transgenic NOD mice after CYP
injection.

Another important question need to be considered is whether the increased susceptibility to CYP
accelerated NOD diabetes can be extended to other types of autoimmune diabetes, such as spontaneous
NOD diabetes and adoptive transfer NOD diabetes. CYP injected NOD mice supposedly develop
autoimmune diabetes with similar pathology as in spontaneous NOD diabetes (Augstein et al. 1998). Beta
cell destruction in each of these models is mediated by the autoimmune reaction. Therefore monitoring the
diabetes incidence in spontaneous NOD diabetes models is necessary for a more complete understanding of
the role of antioxidant trans genes in autoimmune Type 1 diabetes.

The third important factor is to know whether our antioxidant trans gene is expressed ectopically,
especially in the immune system. The insulin promoter is a strong promoter that has been shown in
hundreds of transgenic mice to primarily target the pancreatic beta cell. Recent results indicate that the
promoter is also active in brain cells that express insulin (Dandoy-Dron et al. 1995; Dandoy-Dron et al.
1991). However unlikely, it is possible that the MT transgene is also expressed in immune cells. This
could alter their responsiveness to CYP. We can perform northern blots or immunohistochemistry to
assure that antioxidant transgenes are negligibly expressed in tissues other than pancreatic beta cells.
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Table 5-1. Microsatellite linkage markes for diabetic susceptible alleles
(Idds) homozygous for congenic NOD mice
genetic position (cM)

linkage marker

Idd locus

chromosome

Idd1=H29 /

Chr17

19.5

D17Mit34

Idd2

Chr9

22

D9Mit25

Idd3

Chr3

19.2

D3Mit21

Idd4

Chr11

46

D11Mit320

Idd5

Chr1

40

D1Mit18

Idd6

Chr6

73

D6Mit339

Idd7

Chr7

4

D7Mit20

Idd8

Chr14

3.5

D14Mit222

Idd9

Chr4

82

D4Mit357

Idd10

Chr3

48.5

D3Mit103

Idd11

Chr4

64.6

D4Mit148

Idd12

Chr14

12

D14Mit222

Idd13

Chr2

71

D2Mit395

Idd14

Chr13

syntenic

D13Mit61

Idd15

Chr5

syntenic

D5Mit48

Idd16

Chr17

18

D17Mit50

Idd17

Chr3

39

D3Mit230

Idd18

Chr3

53.3

D3Mit103

Idd19

Chr6

60.5

D6Mit25

Adapted from Serreze DV, et al. (1996) J. Exp. Med. 184:2049-2053, and
modified based on Mouse Genome Database from Jackson Laboratory
(Serreze et al. 1996).
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Table 5-2. Mg2+ concentration for PCR reaction and approximate PCR product size for
each set of microsatellite markers from NOD and FVB strain
Idd locus

NOD size

Approximate

Mg2+ concentration

(bp)

FVB size (bp)

(mM) for peR reaction

linkage marker

Idd1

D17Mit34

126

146

2

Idd2

D9Mit25

136

128

5.8

Idd3

D3Mit21

218

230

3.2

Idd4

011 Mit320

124

128

3.5

Idd5

D1Mit18

170

160

3.2

Idd6

D6Mit339

110

125

3

Idd7

D7Mit20

94

102

4

Idd8/12

D14Mit222

136

120

5

Idd9

D4Mit357

112

105

4.2

Idd10/18

D3Mit103

130

142

3

Idd11

D4Mit148

128

145

3.4

Idd13

D2Mit395

120

162

3

Idd14

D13Mit61

180

170
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Figure 5- L PeR-based genotyping of diabetic susceptible alle les in congenic NOD mice with

~-cell

specific expression of MT transgene. Homozygosity of 19 NOD diabetes loc i (ldd) in the congenic NOD
mice was determined by peR using polymorphic microsatellite markers linked with these Idds. This figure
is a representative ge l graph showing 19 Idds in two MT congenic progenitors (S [, S2), inbred NOD (N),

and FVB (F) mice.
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Pancreati c secti ons in A (NOD) and B (MTNOD) were stain ed with a monoclonal anti -horse MT primary
antibody. Magnification
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400. MT transgene specifically expressed in MTNOD islets at a high level,
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mice. Sections in C (NOD) and 0 (MTNOD) were sta ined with hematoxylin and eosin. Magnification

200. MTNOD mice deve loped similar insuliti s as control NOD mi ce did.
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Figure 5-3. Cumulative diabetes incidence in MT transgenic and nontransgenic NOD mice injected
with CYP. Groups of 16 nontransgenic NOD mice and 15 MT transgenic NOD mice, at the age of 9-10
weeks and sex-matched, were injected with CYP (200mg/kg body weight via ip.) at days 0 and 14 (.&).
Tail blood glucose was monitored every other day. Onset of diabetes was defined when the first of two
consecutive measurements of nonfasting blood glucose levels >200mg/dl was reached. Kaplan-Meier
survival analysis and Mantel-Cox Log-rank test revealed that MT significantly hastened NOD diabetes
onset (P<O.OOI).
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Figure 5-7. Acceleration of diabetes by

~-cell

specific catalase transgene in CYP injected NOD mice.

Groups of 11 nontransgenic NOD mice and 8 catalase transgenic NOD mice (CatNOD), at the age of 5-6
weeks and sex-matched, were injected with CYP (200mg/kg body weight via ip. ) at days 0 and 14 ("').
Diabetes onset was monitored and defined as described in Materials and Methods. Kaplan-Meier survival
analysis and Mantel-Cox Log-rank test revealed that catalase trans gene significantly speeded up NOD
diabetes onset (P<O.05).
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CHATERVI
THE ROLE OF ANTIOXIDANT TRANSGENES
IN AGOUTI OBESE DIABETIC MICE AND NORMAL C57BL/KsJ MICE

Introduction
Several lines of emerging evidence have demonstrated that ROS contribute to pancreatic beta cell
dysfunction and beta cell degeneration in Type 2 diabetes. Chronic exposure to hyperglycemia and
hyperlipidemia probably results in excessive ROS production in pancreatic beta cells (Tanaka et al. 2002;
Listenberger et al. 2001). In both patients (Sakuraba et al. 2002) and animal models of Type 2 diabetes
(Ihara et al. 1999), beta cell oxidative stress markers due to the oxidation of cellular DNA, lipid and protein
are significantly increased. Some antioxidant compounds, such as N-acetylcysteine

(NAC),

aminoguanidine and a-tocopheral have been shown to be beneficial for diabetes treatment. These agents
not only preserved insulin secretory function and improved cell viability in insulin secreting cell lines
exposure to high level of glucose (Tanaka et al. 1999b), but effectively protected from Type 2 diabetes in
animal models (Ihara et al. 2000; Kaneto et al. 1999; Laybutt et al. 2002) as well. A recent study (Tanaka

et al. 2002) reported that adenoviral overexpression of glutathione peroxidase provided protection against
high glucose toxicity by preserving islet insulin mRNA, islet insulin content and secretion in rat islets
treated with high level of ribose. Therefore, a common hypothesis has been proposed that antioxidant
therapy is beneficial to prevent beta cell dysfunction and degeneration in Type 2 diabetes. However, this
concept has not been tested in any in vivo study using animal models of Type 2 diabetes combined with
beta cell specific expression of antioxidants. For this, we produced lines of antioxidant transgenic mouse
crossed with models of Type 2 diabetes. These antioxidant proteins are specifically expressed in beta cells
and thereby their potential site of protection is confined to the beta cells.
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Agouti mice and db/db mice are two animal models which we originally planned to use in this study
to test overexpression of beta cell antioxidants. The Agouti mouse (Michaud et at. 1994), which we
obtained from the Jackson laboratory, is maintained on the inbred KK background. This mouse is
heterozygous for a dominant mutated gene called lethal yellow (Ay) at the Agouti locus (a) of mouse
chromosome 2. Mouse homozygous for Ay gene cannot survive before implantation or shortly thereafter.
But mice heterozygous for the Ay gene are obese and develop Type 2 diabetes (Bultman et at. 1992;
Michaud et at. 1997). The normal murine Agouti gene is transiently expressed only in neonatal skin, where
it causes melanocytes to produce normal pigment (Black fur) (Siracusa 1994). However the mutated form
of the Agouti gene causes a yellow coat color and cause ectopic expression of the Agouti protein in many
other organs. This ectopic expression of the Ay gene makes the mouse develop a form of Type 2 diabeteslike syndrome, with characteristics of human Type 2 diabetes such as obesity, insulin resistance,
hyperinsulinemia, pancreatic islet hypertrophy and hyperplasia (Klebig et al. 1995).

The molecular mechanism by which the agouti protein causes diabetic syndrome is unclear. Some
studies have demonstrated that recombinant agouti protein can coordinately regulate adipocyte lipogenesis
and lipolysis; thereby promoting lipid storage and obesity (Jones et al. 1996; Xue et al. 1998). The
adipocytes from Agouti mice are less sensitive to insulin as assessed by insulin stimulated glucose uptake
and oxidation, indicating that the agouti protein may also cause insulin resistance. Several recent studies
reported that agouti protein regulated cellular Ca2+ signaling in various tissues, including adipocytes (Xue
et al. 1998) and pancreatic islets (Xue et al. 1999). It has been shown that agouti protein is expressed in

human pancreas, and stimulates both Ca2+ signaling and insulin release from human pancreatic islets. This
is a possible reason why hyperinsulinemia occurs in Type 2 diabetes. Agouti protein has also been shown
to stimulate islet amyloid polypeptide release in human pancreatic islets via a Ca2+ dependent mechanism
(Xue & Zemel 2001). The islet amyloid polypeptide is the major component of islet amyloid deposits that
are often found in islets of Type 2 diabetic patients. Excessive amyloid deposits in pancreatic islets is
thought to diminish beta cell mass and cause beta cell dysfunction and degeneration in the later stage of
Type 2 diabetes (Leffert et at. 1989; Lorenzo et at. 1994). Compared to their wild-type counterparts, the
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Agouti mouse has elevated levels of plasma amyloid polypeptide (Warbritton et at. 1994; Verchere et at.
1996).

As indicated above the Agouti mouse we selected in this study was maintained on the KK
background. The KK strain has inherent glucose intolerance and insulin resistance but it has normal blood
glucose and is not obese (Reddi & Camerini-Davalos 1988). But with the addition of the mutated Ay gene,
KK mice become overtly diabetic and obese. By eight weeks of age, the Agouti KK mouse develops
obesity, hyperinsulinemia and hyperglycemia. Male mice are more sensitive than female mice (Klebig et
at. 1995). Since our beta cell antioxidant transgenes are maintained on FVB background, the transgenic

FVB mice were cross-bred with Agouti KK mice to produce F1 mice. We found that those F1 mice,
carrying the Agouti gene (identified by a yellow coat pigment) spontaneously became obese and diabetic.
Therefore in this study we used the Fl Agouti mouse as a model of obesity-associated Type 2 diabetes for
evaluating the potential beneficial effect of beta cell antioxidant transgenes.

Another model of Type 2 diabetes we originally planned to use is the db/db mouse. This type of
mouse is a strain of inbred background called C57BLlKsJ containing a homozygous mutated leptin
receptor gene (Leprdb), usually designated as db/db (Berglund et at. 1978; Leiter et at. 1981). The leptin
ligand/leptin receptor genes play important roles in control of body weight (lgel et at. 1997; Tartaglia
1997). Without a db/db homozygous mutation, the strain of C57BLIKsJ mouse is lean and euglycemic. But
if it carries the db/db homozygous mutation, this background of C57BLIKsJ becomes obese and diabetic.
Introduction of the same db/db mutation onto other genetic backgrounds, such as FVB or C57BLl6J only
results in obesity but not diabetes (Chua S Jr et al. 2002). The reason that the C57BLlKsJ background is
required for db/db mediated Type 2 diabetes is unclear. In db/db mice with a C57BLlKsJ background,
obesity starts around 3 to 4 weeks of age, hyperinsulinemia occurs two weeks after birth and
hyperglycemia develops at 4 to 8 weeks of age. Thus in this study we first placed the antioxidant
trans genes on the C57BLIKsJ background by backcrossing our transgenic FVB mice to C57BLlKsJ mice
up to six times. We next intended to introduce the db/db mutation by further backcrossing with Leprdb
gene heterzygous (db/+) C57BLlKsJ mice. Since C57BLlKsJ mice are normally euglycemic we expected
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that until we added the db/db homozygous mutation that our animals with antioxidant transgenes would be
euglycemic. However, we found that C57BLlKsJ mouse with the MT beta cell transgene developed severe
diabetes even before the db/db mutation was introduced.
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Materials and Methods

Generation of transgenic Agouti FI mice and C57BUKsJ mice. Agouti KK mice and C57BLIKsJ
inbred mice were purchased from Jackson Laboratory and housed in ventilated microisolator cages at the
Research Resource Center in University of Louisville. The mice were fed with standard mouse chow with
free access to tap water.

The transgenic Agouti mice were F I litters produced by the following breeding procedures. MT
transgenic FI Agouti mice were produced by cross-breeding between HMT-I transgenic FVB mice and
Agouti KK inbred mice. MnSOD, catalase and MnSOD plus catalase transgenic FI Agouti mice were
produced by cross-breeding between inbred FVB mice containing both MnSOD and catalase transgenes to
Agouti KK inbred mice. Among the produced FI offspring, half of them were theoretically Ay gene
negative mice with a black coat color, and another half were Ay gene positive mice with a yellow coat
color. The presence of antioxidant transgenes was identified by PCR.

The MT transgenic C57BLIKsJ mice were produced by continuous backcrossing of HMT-I
transgenic FVB mice to C57BLIKsJ inbred mice up for six times. At each generation, the MT transgenic
offspring were determined by PCR.

Monitoring of diabetes and obesity in Agouti Fl mice: The non-fasting tail blood glucose level was
periodically measured with a glucose meter (Ultrasensitive, LifeScan) in the Agouti FI mice and control
mice (non Agouti, non transgenic) shortly after they were weaned. The body weight was also recorded at
the same time. The diabetes onset was defined as the first day when two consecutive measurements of
blood glucose level were higher than 200 mg/dl. Some Agouti FI mice were sacrificed at 3 months and 7
months of age and blood samples were collected for measurement of glycohemoglobin.

Measurement of whole blood glycohemoglobin. The assay of blood glycohemoglobin measurement
was performed by a Glyc-Afin GHb kit from PerkinElmer Life Sciences (Norton, OH). This is an affinity-
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based chromatography assay. Briefly, the mouse blood was collected into a collection microtube coated
with heparin. 50 III of the blood sample was mixed with 400 III sample preparation reagent which was
supplied in the kit. After standing for 10 min with occasional shaking, 50 III of this mixture was added onto
the top disk of the affinity column that was prewashed with preparation solution. The sample mixture was
allowed to flow into the column freely and thereafter the column was washed with 100 III First Fraction
Elution Agent supplied in the kit. Then the elute containing nonglycohemoglobins was collected by adding

3 ml of First Fraction Elution Agent to the column followed by a collection of glycohemoglobin elute
washed by 2 ml of Second Fraction Elution Agent. The nonglycohemoglobin fraction was diluted with
addition of 17ml of distilled water. The optical density of these glycohemoglobin and diluted
nonglycohemoglobin elutes was measured at the wavelength of 405nm. The blood glycohemoglobin
content was calculated as:
%GHb=100*GI (G+lON),

where G=absorbance of the GHb fraction, and N=absorbance of the nonglycohemoglobin fraction.
This formula was provided by the kit.

Diabetes in MT transgenic C57BUKsJ mice: At each generation the offspring were carefully
observed for diabetic symptoms (polyphagic, polydipsic, and polyuric). At certain age or whenever the
mice were found with some diabetic symptoms, the tail blood glucose levels were checked with a glucose
meter (Ultrasensitive, LifeScan). Some mice were sacrificed at different ages and pancreata were removed
for standard histological H&E staining. Both transgenic and nontransgenic mouse pancreatic insulin levels
at different ages were measured with a radioactive immunoassay as described in Materials and Methods of
Part II.
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Results

Obesity and diabetes in Agouti Fl mice. We produced FI mice by cross-breeding between our
heterozygous transgenic FVB mice and heterozygous Agouti KK mice. This breeding procedure generated
littermates carrying 50% of genes from FVB and 50% from KK. Therefore these F 1 mice were genetically
identical except for the Ay gene and our antioxidant transgenes. To evaluate the effect of MnSOD and/or
catalase antioxidant transgenes, we produced FI mice by cross-breeding double transgenic FVB mice
(containing both MnSOD and catalase) and Agouti KK inbred mice. These litters had eight possible
genotypes. Each of them theoretically should occupy one-eighth of the population. Figure 6-1 showed the
body weight and blood glucose levels in five types ofFl male mice. They are control mice (nontransgenic
and non-Agouti), nontransgenic Agouti, MnSOD Agouti, catalase Agouti, and MnSOD+catalase Agouti
mice. Compared with the control mice, all four types of Agouti Fl mice, no matter what kind of trans gene
they carried, developed similar obesity as they aged (Figure 6-1A). Those Agouti Fl mice had a blood
glucose level close to 200 mgldl at the age of one month which was already significant higher than the
control mice. At the age of 2 to 3 months, the blood glucose for all types of Agouti Fl mice climbed to a
level higher than 300 mg/dl, and then maintained there until the end of our observation. There was a
nonsignificant trend for catalase and catalase plus MnSOD transgenic Fl Agouti mice to have greater
hyperglycemia than either Agouti Fl or Agouti MnSOD FI mice. Out data suggest that MnSOD and
catalase trans genes, either alone or in combination, do not significantly affect the progression of diabetes in
Agouti FI obese mice.

We also measured whole blood glycated hemoglobin concentrations in those Agouti FI mice at the
age of 3 months and 7 months. Glycated hemoglobin refers to total glycosylated hemoglobin present in
erythrocytes. It reflects the level of glucose in the blood stream over the previous four to eight weeks.
Compared to blood glucose or urine glucose measurements whose values can vary over the course of a day,
glycated hemoglobin level are more stable. In normal euglycemic mice the glycated hemoglobin value is
reported to be under 6%. In our study, nontransgenic Agouti Fl mice had a glycated hemoglobin level of
5.6% at 3 months of age and elevated to 9% at 7 months of age, indicating a gradual progression of Type 2
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diabetes. However, the antioxidant transgene, either alone (MnSOD or catalase) or combined together, had
no therapeutic value to reduce glycohemoglobin content (Figure 6-2).

To test the role of the MT transgene in Agouti Type 2 diabetes, the HMT-l transgenic FVB mice
were bred with Agouti KK inbred mice. Four types of Fl littermates were produced which were MT
Agouti, nontransgenic Agouti, MT non-Agouti, and nontransgenic non-Agouti. All Agouti mice (MT
transgenic or nontransgenic) developed obesity but non-Agouti mice (MT transgenic or nontransgenic)
were lean (data not shown). We followed the blood glucose in male Fl mice over 4 months. As shown in
Figure 6-3, the control mice with no Agouti gene and no MT transgene maintained euglycemia. But with
the Agouti gene the mice gradually became hyperglycemic. There was no statistical difference between MT
transgenic Agouti mice and nontransgenic Agouti mice although the MT transgenic mice always had a little
higher glucose level. Therefore the MT trans gene did not prevent Type 2 diabetes in Agouti mice.

The effect of the MT transgene in C57BL/KsJ mice. A C57BLIKsJ mouse is a strain with normal
blood glucose throughout life although this strain is unusually sensitive to many diabetogens, such as STZ,
alloxan and certain viruses (Berglund et al. 1988; Blokh et a/. 1988; Leiter et al. 1987a; Leiter et al. 1983).
In our study we placed the MT transgene on C57BLlKsJ background by backcrossing HMT-l transgenic
FVB mice to C57BLIKsJ inbred mice. Since we had not introduced the mutated leptin receptor gene db, the
offspring were not expected to become obese or diabetic. However, even in the Fl generation we
unexpectedly found that MT produced severe diabetes (blood glucose> 600 mgldl) in some offspring. The
severity of diabetes seemed to be age-, sex- and backcross generation dependent (Table 6-1). Now at the
6th generation, 100% of male MT transgenic mice become diabetic at 8 to 10 weeks, and about 40% of
female MT mice become diabetic at the age of 20 weeks. Neither male nor female mice without the MT
trans gene develop diabetes (Figure 6-4). Morphological observation by H&E staining revealed significant
atrophy in pancreatic islets and degeneration of islet cells (Figure 6-5).
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Discussion

In this part of study, we developed several lines ofFI mice heterozygous for the Agouti gene (Ay) by
outbreeding between antioxidant transgenic FVB mice and AgoutilKK mice. The FI nontransgenic Agouti
mice spontaneously developed obesity and hyperglycemia by 6 weeks of age. However the progression of
obesity and diabetes in this strain of mice was not altered by the beta cell antioxidant trans genes; including
MT, catalase, MnSOD and MnSOD plus catalase. These data indicate that antioxidant therapy is not likely
to be beneficial for beta cell function and survival in the Agouti Type 2 diabetic model.

This is the first study to test the effect of antioxidant transgenes against Type 2 diabetes in vivo. The
FI mice obtained by crossbreeding between FVB and Agouti KK mice developed obesity and diabetes.
This makes the Agouti model extremely convenient for testing trans genes against Type 2 diabetes.
Random serum insulin measurements

(Data not shown) indicated that the FI mice were initially

hyperinsulinemic. Pancreatic histology at an early age showed that the Agouti FI mice had very large
islets (Data not shown). Both the hyperinsulinemia and large islets are typical of beta cell compensation
that generally precedes Type 2 diabetes.

However the results were disappointing in that we did not observe any protective effect of our
antioxidant transgenes. These antioxidants were unable to reduce the hyperglycemia in FI Agouti mice.
This indicates the failure of pancreatic beta cells to adequately compensate for insulin resistance is not
likely to be due to oxidative stress.

The finding that MT induced diabetes on the C57BLlKsJ background was extremely surprising.
C57BLlKsJ mice are very sensitive to diabetes from many sources. This appears to be due to the ease with
which their beta cells die.

Most studies on beta cells of C57BLIKsJ mice were done before the

appreciation of the apoptosis process so it has not been determined whether cell death is due to apoptosis or
necrosis.

Overexpression of MT must trigger this death process and the mechanism remains to be
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detennined. It may be related to the increased rate of diabetes onset we found in CYP treated MTNOD
mice, described in Part V.
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Figure 6-1. Body weight (A) and blood glucose level (B) in male Fl control and Agouti mice. Mice
were produced by breeding between MnSOD+Catalase transgenic FVB mice and Agouti/KK mice. Body
weight and blood glucose were measured as described in Materials and Methods. The data at each time
point were mean values from at least three animals. The vertical bars indicate the standard error.
Transgenic and nontransgenic Agouti mice developed similar degree of obesity. None of the antioxidant
transgene prevented Agouti Type 2 diabetes (p>O.05 transgenic vs. nontransgenic agouti mice by one-way
ANOVA).
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Table 6-1. Frequency of diabetic mice in C57BLIKsJ mice at each generation due
to the beta cell MT transgene.

Data are expressed as the number of mice that became diabetic over the total
number of total mice observed in that group. ImICI, ImIC4, ImIC5, ImlC6
refer to IS" 4th, 5th , 6th generation, respectively of backcrossing to C57BLlKsJ
mice.
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Figure 6-4. Frequency of diabetes in MT transgenic and nontransgenic C57BLIKsJ mice. At the sixth

generation backcross of HMT-I positive mice to C57BLIKsJ mice, all males and 40% of female MT
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Figure 6-5. Morphology of pancreatic islets in MT transgenic (MTC57BLKs/J) and nontransgenic
C57BLKs/J mice. The pancreatas 1T0m different aged (50 and 90 days) animals were sectioned and
stained with H&E. MT transgenic islets showed significant islet atrophy and islet cell degeneration. Green
arrows point to distinct vacuole structures commonly present in MT transgenic islets, probabl y left-over
when beta cells undergo apoptosis. Magification x 200.
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SUMMARY AND DIRECTION FOR FUTURE STUDIES

Summary
One of the main goals for diabetes treatment is to prevent pancreatic beta cell death. A large body of
evidence has demonstrated that excessive ROS are fomied in both Type 1 and Type 2 diabetes. Pancreatic
beta cell death is mediated by an autoimmune reaction in Type 1 diabetes (Horio et a/. 1994; Nomikos et

a/. 1989). In Type 2 diabetes beta cell damage is thought to be a consequence of long term exposure to
high level of glucose and/or free fatty acids (Tanaka et a/. 2002; Ihara et al. 1999). In vitro studies using
defined chemical or enzymatic ROS sources have revealed that islet cells are extremely susceptible to ROS
induced cell destruction (Malaisse et al. 1982). This susceptibility may be due to the fact that pancreatic
beta cells contain particularly low level of expression and activity ofROS detoxifying systems compared to
other cell types (Grankvist et al. 1981 b; Lenzen et a/. 1996). A number of studies, which were carried out
mostly in vitro using insulin secreting tumor cell lines or isolated islets, have reported that elevated
antioxidant protein expression in beta cells, obtained by gene transfer techniques or application of ROS
scavenger compounds, protects from ROS destruction (Lortz et a/. 2000; Tiedge et al. 1998; Tiedge et al.
1999). Hence the antioxidant is expected to produce a protective effect in vivo. However, the translation of
this notion to in vivo studies from the in vitro results is very unclear. Attempts to use antioxidant therapy to
treat animal or human diabetes have shown conflicting and questionable results (Welsh et al. 1994c;
Burkart & Kolb 1993; Piercy et al. 2000; Berglund et al. 1988; Sandstrom et al. 2002). This may be
because prolonged high level, in vivo treatment with antioxidants is difficult to achieve and it is not tissue
specific. As a result the studies of this project were designed to clarify this ambiguity. The overall purpose
of this project was to perform an in vivo test of whether direct antioxidant protection of pancreatic beta
cells could prevent Type 1 or Type 2 diabetes.
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To achieve this aim, several lines of transgenic mice with beta cell specific expression of antioxidants
including MnSOD, catalase, MnSOD plus catalase, and MT were created on the FVB strain of mice. These
trans genes were specifically expressed in pancreatic beta cells at a high level but without detectable
damage to normal beta cell function and structure. These transgenic animals provided us with an optimal
model to perform the in vivo test of the potential effect of antioxidant therapy on diabetes.

In this study we have demonstrated that the transgenic beta cells or transgenic animals are highly
resistant to oxidative damage. By measuring CM-H2DCFDA oxidation, the pancreatic islet cells containing
antioxidant transgene (s) were shown to be highly effective in scavenging ROS. The transgenic islets
generally survived and functioned better than control islets when exposed to various ROS insults, including
H 20 2, NO and STZ. More importantly, in vivo all of these antioxidant transgenes reduced STZ induced
diabetes and beta cell morphological disruption. This protective effect was due to protection from ROS
since STZ induced pancreatic beta cell oxidative damage marker nitrotyrosine was remarkably reduced in
transgenic islets. Moreover, the combination of MnSOD and catalase made the beta cells more effective in
scavenging some types of ROS and more resistant to STZ induced beta cell destruction and diabetes than
either transgene alone. These results are consistent with published in vitro data (Lortz et at. 2000; Tiedge et

at.

1998). Those in vitro studies aimed to develop a robust beta cell line with enhanced resistance to

oxidative stress. Now such a goal has been achieved in a whole animal in this project. We have developed
transgenic FVB mice with beta cell specific antioxidant protection that produces great resistance to ROS
damage and STZ induced diabetes.

We anticipated that these antioxidant protected beta cells should also be very resistant to cytokine
toxicity, and that these antioxidant transgenic mice should be protected from Type 1 and Type 2 diabetes.
However, the results from the rest of the project were disappointing but interesting and probably very
valuable. Unlike insulin secreting cell lines exposed to cytokines, our primary mouse beta cells with
antioxidant overexpression lost cellular function and died exactly the same as control cells as indicated by
insulin secretory function and islet cell metabolic activity. Cytokine induced beta cell iNOS expression and
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NO production were not inhibited by antioxidant trans gene expression. These results suggest a negligible
impact of ROS and antioxidants in mediation of cytokine toxicity to primary mouse beta cells.

The lack of benefit of antioxidant proteins was also true in Type 2 diabetes models. In these studies
new lines of obese and diabetic mice heterozygous for the Agouti gene were produced with beta cell
antioxidant transgenes. No antioxidant trans gene was shown protective against Type 2 diabetes onset and
development in these mice. This is the first in vivo study using transgenic animal to test whether
antioxidant proteins are beneficial for prevention of Type 2 diabetes. Obviously the answer is no, at least in
the Agouti obese model.

A most interesting and most unexpected finding in this study was obtained with Type 1 diabetic NOD
mice and largely normal C57BLlKsJ mice. Two new lines of NOD mice congenic for beta cell MT and
catalase were independently established. Very surprisingly both MT and catalase transgenes accelerated
NOD diabetes onset after injection of CYP. Several potential artifacts have been ruled out that could
explain this result: In vitro studies showed that metallothionein did not directly sensitize islets to CYP, in
fact it provided significant protection. Prior to CYP injection pancreatic insulin, islet morphology and beta
cell apoptosis were the same in transgenic and nontransgenic NOD mice. In C57BLIKsJ mice that were
originally normal and euglycemic, introduction of the beta cell MT transgene impaired beta cells and
caused severe diabetes as early as 40 to 50 days of age. These data demonstrate that the antioxidants
themselves impair beta cell survival in CYP injected NOD mice and C57BLlKsJ mice. This implies that
ROS may not only be harmful but they may also be necessary for beta cell survival under some kinds of
diabetic stress, for example immune stress in NOD mice.

This new hypothesis is a challenge to the current notion that ROS act only to destroy pancreatic beta
cells, and antioxidant treatment must be beneficial in treating diabetes. However our hypothesis probably is
supported by emerging evidence obtained in many cell types indicating that ROS participate in cellular
signal transduction, probably even in the beta cell.
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However, it needs to be pointed out that all the colonies maintained in the animal facilities of the
University of Louisville by our laboratory currently are infected with mouse Parvovirus (MPV). MPV is
one of the most prevalent infectious pathogens in research institutions (Besselsen et al. 2000). MPV often
replicates in mitotically active tissues, such as gastrointestinal tract, lymphocytes, and tumors. MPV has
high resistance to temperature and harsh environmental conditions. In vivo, MPV can remain infectious for
a very long time after initial exposure, even in adult mice (Jacoby et al. 1996). In general, MPV infection
causes no clinical symptoms or diseases in infected infant or adult mice, whether they are
immunocompetent or severely immunocomprised (SCID mice) (Jacoby et a/. 1995). But MPV infections
can alter immune function. CD8+ and CD4+ cell function may be inhibited (McKisic et al. 1996; BallGoodrich et al. 1998). Lymphocytes from the spleen and popliteal lymph nodes showed inhibited function
in one study (Nicklas 1999). Therefore in NOD mice MPV contamination theoretically could delay
diabetes onset instead of accelerating it, as revealed in our project. However, we cannot be certain what
impact MPV infection has on NOD mice and C57BLKs/J mice in our studies. Our results need to be
replicated in mice free ofMPV infection that are housed in pathogen-free facilities.

Direction (or Future Studies

It has been recognized for long time that ROS are produced in aerobic cells as by-products during

mitochondrial electron transport, by several oxidoreductases and by metal-catalyzed oxidation of
metabolites (Baynes 1991; Forman & Torres 2001; Nakamura et al. 1997). But classically they are viewed
solely as a toxic evil to the aerobic cells. Recently it has been appreciated that ROS also participate in cell
signal transduction as signal molecules, especially in proinflammatory cytokine and growth factor mediated
cell signaling:

ROS in cytokine and growth factor mediated cell signaling. Analysis of cells in culture has
demonstrated that a variety of ligands including platelet-derived growth factor (PDGF), epidermal growth
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factor (EGF), angiotensin II, as well as a host of cytokines, all trigger the rapid production of intracellular
ROS. These endogenously produced ROS act as second messengers to stimulate protein kinase cascades
coupled to gene expression, or control of cell cycle (Kamata & Hirata 1999).

H20 2 is the first identified endogenous ROS involved in cellular signaling. In vascular smooth muscle
cells, activation of PDGF caused peroxide formation which could be inhibited by intracellular expression
of catalase. Antioxidant N-acetyl-cysteine inhibited the activation ofPDGF receptor-coupled protein kinase
cascades (Sundaresan et at. 1995). Similarly EGF signaling also involves H20 2 formation. In human
epidermoid carcinoma cells EGF resulted in a transient increase in the intracellular concentration of ROS,
measured with the oxidation-sensitive fluorescent probe 2',7'-dichlorofluorescin diacetate and laserscanning confocal microscopy. Application of catalase by electroporation abolished DCF fluorescence and
inhibited EGF-induced tyrosine phosphorylation (Bae et al. 1997). The involvement of ROS in insulin
signaling has also been reported. H20 2 was found to have insulin-like stimulating effect on various cell
types, including adipocytes, leukocytes and hepatoma cells. There are reports showing H20 2 increased
insulin receptor kinase activity by increasing phosphorylation of the insulin receptor. A direct measurement
by DCF fluorescent probes revealed that H20 2 was formed in human polymorphonuclear leukocytes
(PMNLs) treated with insulin. This increase of H20 2 was enhanced by a PKC stimulator but partially
inhibited by a PKC inhibitor (Spagnoli et al. 1995). Several studies have demonstrated that peroxide can
mediate cytokine signaling. In primary rat astrocytes, both interleukin-l P and H20 2 promoted phosphoactivation of the P3s-mitogen activated protein kinase. A direct measurement showed that H20 2 formation
was increased in IL-IP treated astrocytes, which could be suppressed by the antioxidants N-acetyl-cysteine
and the nitrone-base antioxidant phenyl-N-tert-butylnitrone (PBN). Although there are no reports showing
ROS involvement in beta cell signaling after cytokine or growth factor treatment, it is reasonable to expect
that such kinds of signaling exist in beta cells. Both cytokine and insulin receptors are highly expressed on
pancreatic beta cell membranes. Cytokines have important actions in beta cells (Maedler et at. 2002).
More and more studies have shown that insulin signaling is important for beta cell function and survival.
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Protein Tyrosine Phosphatases - important targets regulated by ROS.

Although many studies

have indicated the presence of endogenous ROS-sensitive signal transduction pathways, the exact targets
regulated by ROS are just starting to be identified, such as NF-KB, AP-l and JNK. Among of those, protein
tyrosine phosphatase (PTP) is emerging as one of the most important ROS regulated targets related to
diabetes pathology.

PTPs, coordinating with protein tyrosine kinases, play an important role in

maintaining a normal tyrosine phosphorylation status in vivo. Aberrant tyrosine phosphorylation due to
disturbance of the balance between protein tyrosine kinase and PTPs function has been implicated in the
etiology of several human diseases, including cancer, diabetes and inflammation (Tonks & Neel 2001).
Many studies have shown PTPs are major targets for H20 2• PTPs contain an essential catalytic cysteine
residue in their active sites, which is extremely reactive, with a lower pKa (about 5.5) than the pKa (about
8) of cysteine residues in most other proteins (Peters et al. 1998). The low pKa makes the thiolate anion
especially susceptible to the inhibitory action of ROS by forming a sulfenic acid (Cys-sOH) intermediate.
This transient intermediate could be reversed by a thiol-reducing agent such as glutathione. It has been
reported H20 2 treatment could inhibit PTPs in vitro (Denu & Tanner 1998) as well as in several cell lines
such as HER14 cells (Sullivan et al. 1994), Jurkat T lymphocytes (Secrist et al. 1993) and HELA cells
(Cunnick et al. 1998). Antioxidants such as N-acetylcysteine (NAC) inhibits H20 2-induced phosphatase
inactivation in glia cell lysate (Robinson et al. 1999). More importantly, there are reports showing that
endogenous H20 2 production after insulin stimulation reversibly inactivated PTP-IB and enhanced the
early insulin signal cascade (Tao et al. 2001). This reversible inhibition of PTPs could be abolished by
catalase. Therefore the inhibition ofPTPs by ROS has been thought to be a physiologically important event
during cell signaling by insulin.

A growing body of evidence has emerged to support the concept that PTPs play an important role in
obesity and diabetes. Several PTPs have been identified in major insulin-sensitive tissues, such as skeletal
muscle, liver, and adipose tissue. PTP-lB-deficient mice show increased insulin sensitivity in muscle and
liver, and resistance to obesity (Elchebly et al. 1999). When these knock-out mice are crossed onto ob/ob
mice, improvement in blood glucose and obesity is seen. When PTP-lB antisense oligonucleotides are
administered in vivo to ob/ob mice, normalized blood glucose levels are obtained. However the
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overexpression of PTP-lB inhibits proximal and distal insulin signaling events. Therefore, PTP-l B is
considered to be involved in the etiology of diabetes mellitus.

Insulin signaling and beta cell fate. The insulin signaling pathway is initiated by tyrosine
autophosphorylation of the insulin receptor followed by several different cellular scaffold proteins binding
to the autophosphorylation sties. Then the multiple tyrosine residues of a series of key post-receptor
substrate proteins are phosphorylated. Most of these cellular scaffold proteins are tyrosine-phosphorylated
proteins. Therefore the insulin signaling is balanced by the action of specific protein-tyrosine phosphatases
(PTPs). PTPase activity, in tum, is highly regulated in vivo by oxidation/reduction reactions involving the
cysteine thiol moiety required for catalysis.

Although the roles of those various insulin receptor scaffold proteins merit attention, recent work with
transgenic mice suggests that many insulin responses, especially those that are associated with somatic
growth and carbohydrate metabolism, are largely mediated through two insulin receptor substrate (IRS)
proteins, called IRS-l and IRS-2. In pancreatic islets, recent data has reported that IRS-2 branch of
insulin/IGF signaling playa key role in beta cell survival and function (Withers et at. 1999; White 2002).
In mice, both IRS-l knock out and IRS-2 knock out mice have remarkable induced insulin resistance;
however, only IRS-2 knock out mice fail to sustain compensatory insulin secretion due to decreased beta
cell mass compared with wild-type and IRS-l knock out mice. Those IRS-2 knock out mice eventually
developed diabetes. These data suggest that the convergence of peripheral and islet defects around the IRS2 branch of the insulin/IGF signaling pathway may reveal the common pathway to diabetes. These data
demonstrate the importance of insulin signaling for beta cell survival. We also know that insulin signaling
is positively effected by ROS through inhibition ofPTPs.

In type I diabetic patients and in transgenic NOD mice, we know that during immune attack the beta
cells are exposed to many stressors including lymphocytes and cytokines. In response to these stimuli we
propose that the pancreatic beta cell will first trigger their defense system by activating IRS-2 related cell
signaling pathways. Since insulin, cytokine-IRS signaling is highly regulated by oxidant state sensitive
PTPs, we suspect that both our antioxidant transgenes MT and catalase may inhibit this insulin, cytokine-
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IRS signaling pathway by scavenging cytokine induced ROS in the beta cells, and thereby suppress normal
beta cell survival responses. This new hypothesis emphasizes the fact that ROS have survival stimulating
roles in addition to toxic actions in the beta cell. Confirming this hypothesis may reveal new approaches to
protect the beta cell and thus reduce diabetes.
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APPEENDIXA
LIST OF ABBREVIATIONS

NO
8-0HDG
AEC
AG
AGEs
AP-l
Ay gene
BB rat
BSA
Cat
CM-H2DCFDA
CulZn SOD
Cyp
DAB
db
db/db mice
ECSOD
EGF
ER
FBS
FFAs
GHb
GKrat
GLUT2
Gpx
H 20 2

HBSS
HNE

HO

HX
Idd
IFN-y
IL-l~

iNOS
IRS
JNK
KRB buffer
Leprdb gene

nitric oxide
8-hydroxydeoxyguanosine
3-amino-ethylcarbazone
amino guanidine
advanced glycosylation end-products
activating protein-l
Agouti gene
Bio-Breeding rat
bovine serum albumin
catalase
5-(6)-chloromethyl-2', 7' -dichlorodihydrofluorescein diacetate
Copper- and Zinc- containing superoxide dismutase
cyclophosphamide
3, 3' -diaminobenzidine
leptin receptor mutant allele
obese mice on C57BLIKsJ background containing homozygous
leptin receptor mutant gene
extracellular superoxide dismutase
epidermal growth factor
endoplasmic reticulum
fetal bovine serum
free fatty acids
glycohemoglobin
Goto-Kakizaki rat
glucose transporter 2
glutathione peroxidase
hydrogen peroxide
Hanks' balanced salt solution
4-hydroxy-nonenal
hydroxyl radical
hypoxanthine
diabetic susceptible allele
interferon-gamma
interleukin-l beta
inducible nitric oxide synthase
insulin receptor substrate
c-Jun-N-terminal kinase
Krebs-Ringer bicarbonate buffer
leptin receptor mutant gene
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MDA
MnSOD
MPV
MT
MTT
NAC
NF-KB
NO
NOD mouse
NOS
O

2

'-

ob/ob mice
PARP
PBN
PBS
PDGF
PMNLs
PTPs
real time RT-PCR

RNS
ROS
SIN-l
SNAP
SOD
~-cell

STZ
TAE buffer
TNF-a

Tpx

XO
ZDF rats

malondialdehyde
manganese superoxide dismutase
mouse parvovirus
metallothionein
3-[4,5 -dimethylthiazo1-2-y 1] -diphenly Itetrazo Ii urn bromide
N-acety 1-L-cysteine
Nuclear factor-kappaB
nitric oxide
non-obese diabetic mouse
nitric oxide synthase
superoxide anion (radical)
obese mice on C57BLl6 background containing homozygous
leptin ligand mutant gene
poly (ADP-ribose) polymerase
phenyl-N-tert-butylnitrone
phosphate-buffered saline
platelet-derived growth factor
human polymorphonuclear leukocytes
protein-tyrosine phosphatases
real time reverse transcriptase polymerase chain reaction
reactive nitrogen species
reactive oxygen species
3-morpholinosydnonimine
S-nitro-N-acety I-penicillamine
superoxide dismutases
pancreatic beta cell
streptozotocin
Tris-acetate-EDTA buffer
tumor necrosis factor-alpha
thioredoxin peroxidase
xanthine oxidase
zucker diabetic fat rats
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